<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for treating intrahepatic cholestasis of pregnancy - Walker, KF - 2020 | Cochrane Library</title> <meta content="Pharmacological interventions for treating intrahepatic cholestasis of pregnancy - Walker, KF - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000493.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for treating intrahepatic cholestasis of pregnancy - Walker, KF - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000493.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000493.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for treating intrahepatic cholestasis of pregnancy" name="citation_title"/> <meta content="Kate F Walker" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Lucy C Chappell" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="William M Hague" name="citation_author"/> <meta content="Philippa Middleton" name="citation_author"/> <meta content="Healthy Mothers, Babies and Children, South Australian Health and Medical Research Institute" name="citation_author_institution"/> <meta content="Jim G Thornton" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="jim.thornton@nottingham.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD000493.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000493.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000493.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000493.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Charcoal [therapeutic use]; Cholagogues and Choleretics [therapeutic use]; Cholestasis [complications, *therapy]; Cholestyramine Resin [therapeutic use]; Dexamethasone [therapeutic use]; Drugs, Chinese Herbal [therapeutic use]; Fetal Distress [epidemiology]; Galactans [therapeutic use]; Glucocorticoids [therapeutic use]; Mannans [therapeutic use]; Plant Gums [therapeutic use]; Pregnancy Complications [*therapy]; Pruritus [etiology, *therapy]; Randomized Controlled Trials as Topic; S-Adenosylmethionine [therapeutic use]; Stillbirth [epidemiology]; Ursodeoxycholic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000493.pub3&amp;doi=10.1002/14651858.CD000493.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000493\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000493\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000493.pub3",title:"Pharmacological interventions for treating intrahepatic cholestasis of pregnancy",firstPublishedDate:"Jul 27, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pregnancy and Childbirth Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000493.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000493.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000493.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000493.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000493.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000493.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000493.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000493.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000493.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000493.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12021 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000493.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-sec-0291"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-sec-0285"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/appendices#CD000493-sec-0296"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/table_n/CD000493StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/table_n/CD000493StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for treating intrahepatic cholestasis of pregnancy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#CD000493-cr-0004">Kate F Walker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#CD000493-cr-0005">Lucy C Chappell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#CD000493-cr-0006">William M Hague</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#CD000493-cr-0007">Philippa Middleton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information#CD000493-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Jim G Thornton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information/en#CD000493-sec-0306">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000493.pub3">https://doi.org/10.1002/14651858.CD000493.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000493-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000493-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000493-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000493-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000493-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000493-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000493-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000493-abs-0001" lang="en"> <section id="CD000493-sec-0001"> <h3 class="title" id="CD000493-sec-0001">Background</h3> <p>Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that can develop in pregnancy. It occurs when there is a build‐up of bile acids in the maternal blood. It has been linked to adverse maternal and fetal/neonatal outcomes. As the pathophysiology is poorly understood, therapies have been largely empiric. As ICP is an uncommon condition (incidence less than 2% a year), many trials have been small. Synthesis, including recent larger trials, will provide more evidence to guide clinical practice. This review is an update of a review first published in 2001 and last updated in 2013. </p> </section> <section id="CD000493-sec-0002"> <h3 class="title" id="CD000493-sec-0002">Objectives</h3> <p>To assess the effects of pharmacological interventions to treat women with intrahepatic cholestasis of pregnancy, on maternal, fetal and neonatal outcomes. </p> </section> <section id="CD000493-sec-0003"> <h3 class="title" id="CD000493-sec-0003">Search methods</h3> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register, <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>, the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) (13 December 2019), and reference lists of retrieved studies. </p> </section> <section id="CD000493-sec-0004"> <h3 class="title" id="CD000493-sec-0004">Selection criteria</h3> <p>Randomised or quasi‐randomised controlled trials, including cluster‐randomised trials and trials published in abstract form only, that compared any drug with placebo or no treatment, or two drug intervention strategies, for women with a clinical diagnosis of intrahepatic cholestasis of pregnancy. </p> </section> <section id="CD000493-sec-0005"> <h3 class="title" id="CD000493-sec-0005">Data collection and analysis</h3> <p>The review authors independently assessed trials for eligibility and risks of bias. We independently extracted data and checked these for accuracy. We assessed the certainty of the evidence using the GRADE approach. </p> </section> <section id="CD000493-sec-0006"> <h3 class="title" id="CD000493-sec-0006">Main results</h3> <p>We included 26 trials involving 2007 women. They were mostly at unclear to high risk of bias. They assessed nine different pharmacological interventions, resulting in 14 different comparisons. We judged two placebo‐controlled trials of ursodeoxycholic acid (UDCA) in 715 women to be at low risk of bias. </p> <p>The ten different pharmacological interventions were: agents believed to detoxify bile acids (UCDA) and S‐adenosylmethionine (SAMe); agents used to bind bile acids in the intestine (activated charcoal, guar gum, cholestyramine); Chinese herbal medicines (yinchenghao decoction (YCHD), salvia, Yiganling and Danxioling pill (DXLP)), and agents aimed to reduce bile acid production (dexamethasone) </p> <p>Compared with placebo, UDCA probably results in a small improvement in pruritus score measured on a 100 mm visual analogue scale (VAS) (mean difference (MD) −7.64 points, 95% confidence interval (CI) −9.69 to −5.60 points; 2 trials, 715 women; GRADE moderate certainty), where a score of zero indicates no itch and a score of 100 indicates severe itching. The evidence for fetal distress and stillbirth were uncertain, due to serious limitations in study design and imprecision (risk ratio (RR) 0.70, 95% CI 0.35 to 1.40; 6 trials, 944 women; RR 0.33, 95% CI 0.08 to 1.37; 6 trials, 955 women; GRADE very low certainty). </p> <p>We found very few differences for the other comparisons included in this review.</p> <p>There is insufficient evidence to indicate if SAMe, guar gum, activated charcoal, dexamethasone, cholestyramine, Salvia, Yinchenghao decoction, Danxioling and Yiganling, or Yiganling alone or in combination are effective in treating women with intrahepatic cholestasis of pregnancy. </p> </section> <section id="CD000493-sec-0007"> <h3 class="title" id="CD000493-sec-0007">Authors' conclusions</h3> <p>When compared with placebo, UDCA administered to women with ICP probably shows a reduction in pruritus. However the size of the effect is small and for most pregnant women and clinicians, the reduction may fall below the minimum clinically worthwhile effect. The evidence was unclear for other adverse fetal outcomes, due to very low‐certainty evidence. There is insufficient evidence to indicate that SAMe, guar gum, activated charcoal, dexamethasone, cholestyramine, YCHD, DXLP, Salvia, Yiganling alone or in combination are effective in treating women with cholestasis of pregnancy. There are no trials of the efficacy of topical emollients. </p> <p>Further high‐quality trials of other interventions are needed in order to identify effective treatments for maternal itching and preventing adverse perinatal outcomes. It would also be helpful to identify those women who are mostly likely to respond to UDCA (for example, whether bile acid concentrations affect how women with ICP respond to treatment with UDCA). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000493-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000493-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000493-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000493-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000493-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000493-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000493-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000493-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000493-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000493-abs-0002" lang="en"> <h3>Interventions for treating intrahepatic cholestasis of pregnancy (ICP)</h3> <p><b>What is the issue?</b> </p> <p>A liver disorder arising during pregnancy, most often in the last three months, commonly causes itching (pruritus), which can be extremely distressing to the pregnant woman. Bile acids accumulate within the liver and the blood concentration of bile acids is raised, although not always apparent with the symptoms. The signs and symptoms often resolve spontaneously within the first few days after birth, and usually within four to six weeks. Although the condition is poorly understood, there is an association with preterm birth and stillbirth among women with the severest forms of the disease. Many treatments have been suggested. This review is an update of a review first published in 2001 and last updated in 2013. </p> <p><b>Why is this important?</b> </p> <p>The itching can be disabling. Stillbirth and preterm birth are serious adverse outcomes which are important to prevent. </p> <p><b>What evidence did we find?</b> </p> <p>We searched for evidence in December 2019, and identified 26 trials involving 2007 women. The trials assessed nine different interventions, but for most of them the trials were small and had a high risk of bias; we were therefore unable to draw firm conclusions. However, the most widely‐used treatment, ursodeoxycholic acid (UDCA), for which we identified seven trials (1008 women), included two trials at low risk of bias (755 women). There is now evidence that UDCA probably reduces itching (moderate‐certainty evidence). However, the size of the effect is small and for many pregnant women may not be worthwhile. The evidence for an effect of UCDA on stillbirth or fetal distress is unclear, mainly due to limitations in study design and imprecise results (very low‐certainty evidence). </p> <p><b>What does this mean?</b> </p> <p>Although UDCA has not been shown to prevent the adverse outcomes of intrahepatic cholestasis of pregnancy, there is no other effective treatment for this condition, and there is a small reduction in maternal itch. </p> <p>More high‐quality trials of other treatments are needed in order to identify what is effective for maternal itching and to prevent adverse outcomes. It would also be helpful to identify those women who are mostly likely to respond to UDCA (for example, whether bile acid concentrations affect how women with ICP respond to treatment with UDCA). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000493-sec-0291" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000493-sec-0291"></div> <h3 class="title" id="CD000493-sec-0292">Implications for practice</h3> <section id="CD000493-sec-0292"> <p>Compared with placebo, UDCA probably shows a reduction in pruritus. However the size of the effect is small and for most pregnant women and clinicians, the reduction may fall below the minimum clinically worthwhile effect. There may be a place for it in offering a test period to a woman for managing pruritus if itching is severe. The evidence was unclear for other adverse fetal outcomes, due to very low‐certainty evidence. </p> <p>There is insufficient evidence to indicate that SAMe, guar gum, activated charcoal, dexamethasone, cholestyramine, YCHD, DXLP, Salvia, Yiganling, alone or in combination, are effective in treating women with cholestasis of pregnancy. There are no trials of the efficacy of topical emollients. </p> </section> <h3 class="title" id="CD000493-sec-0293">Implications for research</h3> <section id="CD000493-sec-0293"> <p>We need new treatments for ICP for prevention of itching and of adverse perinatal outcomes, as well as identifying women who may respond to UDCA. </p> <p><b>Recommendations for future research</b> </p> <p>· In women with ICP:</p> <p>‐ What is an effective treatment for itching?</p> <p>‐ What is an effective treatment to prevent adverse perinatal outcomes?</p> <p>‐ Does the response to UDCA vary by baseline characteristics such as baseline bile acid concentrations? </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000493-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000493-sec-0008"></div> <div class="table" id="CD000493-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ursodeoxycholic acid (UDCA) versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ursodeoxycholic acid (UDCA)</b> <b>compared with placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> pregnant women with intrahepatic cholestasis </p> <p><b>Settings:</b> UK (2 RCTs), Chile, China, Finland, Italy, Sweden (one RCT each) </p> <p><b>Intervention:</b> UDCA </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>UDCA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pruritus score*</p> <p>(points out of 100 mm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean of the worst pruritus score in the placebo group ranged from 56.9 to 61.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean of the worst pruritus score in the intervention groups was 7.64 lower (9.69 lower to 5.60 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>715 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*worst score in previous 24 hours</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stillbirth</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9/1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.51/1000 (0.72 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33 (0.08 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>955 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a small number of events and a wide CI</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal distress/asphyxial events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117/1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82/1000 (41 to 164)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70 (0.35 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>944 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>UDCA:</b> ursodeoxycholic acid. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded one level for serious imprecision, due to there being only two trials, one relatively small.<br/><sup>b</sup> We downgraded two levels for very serious limitations in study design, due to two RCTs not having adequate randomisation and a third RCT with high losses to follow‐up.<br/><sup>c</sup>We downgraded one level for serious imprecision, due to a small number of events and wide confidence intervals.<br/><sup>d</sup>We downgraded one level for serious imprecision, due to wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000493-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000493-sec-0009"></div> <section id="CD000493-sec-0010"> <h3 class="title" id="CD000493-sec-0010">Description of the condition</h3> <section id="CD000493-sec-0011"> <h4 class="title">Introduction and definition</h4> <p>Intrahepatic cholestasis of pregnancy (ICP: also known as obstetric cholestasis) is a pregnancy‐specific liver condition appearing most often in the third trimester. It is a relatively benign but often very distressing condition for the woman, but it may adversely affect fetal outcome, as seen by associations with preterm labour, fetal distress and stillbirth, particularly in severe cases. The diagnosis of ICP is based on a combination of pruritus (itching), which classically affects palms and soles but may become generalised, but without a rash apart from excoriations, together with increased concentrations of serum bile acids (values usually at least 10 μmol/L, or above the upper limit of the normal range for the local laboratory). Increased concentrations of serum transaminases (e.g. alanine aminotransferase (ALT)) greater than 50 U/L are often seen. There is now movement towards an international consensus that the diagnosis should only be made if serum bile acids are increased, irrespective of whether serum transaminases are increased, either alone or in combination. </p> <p>Clinical pruritus may precede the development of abnormal biochemistry (<a href="./references#CD000493-bbs2-0073" title="KenyonAP , PiercyCN , GirlingJ , WilliamsonC , TribeRM , ShennanAH . Pruritus may precede abnormal liver function tests in pregnant women with obstetric cholestasis: a longitudinal analysis. BJOG: an international journal of obstetrics and gynaecology2001;108(11):1190-2. [MEDLINE: 11762661]">Kenyon 2001</a>). Following birth, there is usually spontaneous relief of signs and symptoms within the first few days, although occasionally resolution may take several weeks (<a href="./references#CD000493-bbs2-0058" title="European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. Journal of Hepatology2009;51(2):237-67. [PMID: 19501929]">EASL guidelines 2009</a>). Ongoing clinical symptoms and abnormal liver biochemical values for longer than six weeks after birth may not be consistent with a primary diagnosis of intrahepatic cholestasis of pregnancy, and other causes should be considered. Histopathology of the liver shows non‐specific mild intrahepatic cholestasis with accumulation of bile pigments in hepatocytes and bile duct swelling (<a href="./references#CD000493-bbs2-0065" title="HeikkinenJ , MaentaustaO , YlostaloP , JanneO . Changes in serum bile acid concentrations during normal pregnancy, in patients with intrahepatic cholestasis of pregnancy and in pregnant women with itching. British Journal of Obstetrics and Gynaecology1981;88(3):240-5.">Heikkinen 1981</a>). Accumulation of bile acids within the liver increases serum bile acid concentrations, which may cause pruritus, perhaps due to increased availability of brain opiate receptors (<a href="./references#CD000493-bbs2-0071" title="JonesEA , BergasaNU . The pruritus of cholestasis: from bile acids to opiate antagonists. Hepatology1990;11:884-7.">Jones 1990</a>), although the fact that pruritus may precede abnormal chemistry, including changes in serum bile acids, suggests that other mechanisms may be at work, potentially mediated through serum autotaxin activity (<a href="./references#CD000493-bbs2-0080" title="KremerAE , BolierR , DixonPH , GeenesV , ChambersJ , TolenaarsD , et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. Journal of Hepatology2015;62(4):897-904. [PMID: 25450205]">Kremer 2015</a>) and progesterone sulphated metabolite concentrations (<a href="./references#CD000493-bbs2-0039" title="Abu-HayyehS , OvadiaC , LieuT , JensenDD , ChambersJ , DixonPH , et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology (Baltimore, Md.)2016;63(4):1287-98. [PMID: 26426865]">Abu‐Hayyeh 2016</a>). </p> </section> <section id="CD000493-sec-0012"> <h4 class="title">Epidemiology</h4> <p>The incidence may vary across ethnic groups. It has been reported in fewer than 1% of pregnancies in Central and Western Europe, North America and Australia, in 1% to 2% in Scandinavia and the Baltic states, but can be as high as 5% to 15% in Araucanian Indians in Chile and Bolivia (<a href="./references#CD000493-bbs2-0082" title="LammertF , MarshallHU , GlantzA , MaternS . Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. Hepatology2000;33(6):1012-21.">Lammert 2000</a>). </p> </section> <section id="CD000493-sec-0013"> <h4 class="title">Pathophysiology</h4> <p>The exact pathophysiology is unknown but genetic, endocrine and environmental factors have been implicated. The role of genetics remains unsubstantiated but in high‐prevalence areas a strong family history is often present (<a href="./references#CD000493-bbs2-0044" title="BergB , HelmG , PetersohnL , TrydingN . Cholestasis of pregnancy. Clinical and laboratory studies. Acta Obstetricia et Gynecologica Scandinavica1986;65(2):107-13.">Berg 1986</a>; <a href="./references#CD000493-bbs2-0059" title="ElorantaML , HeinonenS , MononenT , SaarikoskiS . Risk of obstetric cholestasis in sisters of index patients. Clinical Genetics2001;60(1):42-5. [MEDLINE: 11531968]">Eloranta 2001</a>; <a href="./references#CD000493-bbs2-0099" title="QiuZD , WangQN , LiuYH , Miao HZ. Intrahepatic cholestasis of pregnancy: clinical analysis and follow up of 22 cases. Chinese Medical Journal (English)1983;96(12):902-6.">Qui 1983</a>; <a href="./references#CD000493-bbs2-0103" title="ReyesH , RibaltaJ , Gonzalez-CeronM . Idiopathic cholestasis of pregnancy in a large kindred. Gut1976;17(9):709-13. [MEDLINE: 976812]">Reyes 1976</a>; <a href="./references#CD000493-bbs2-0113" title="ShawD , FrohlichJ , WittmannBA , WillmsM . A prospective study of 18 patients with cholestasis of pregnancy. American Journal of Obstetrics and Gynecology1982;142(6 Part 1):621-5.">Shaw 1982</a>). It is thought that mutations of bile acid transporter genes may impair maternal excretion and affect transplacental passage of maternal serum bile acids (<a href="./references#CD000493-bbs2-0057" title="DixonPH , SambrottaM , ChambersJ , Taylor-HarrisP , SyngelakiA , NicolaidesK , et al. An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Scientific Reports2017;7(1):11823.">Dixon 2017</a>; <a href="./references#CD000493-bbs2-0093" title="MilkewiczP , EliasE , WilliamsonC , WeaverJ . Obstetric cholestasis. BMJ2002;324(7330):123-4.">Milkiewicz 2002</a>). Familial disorders such as progressive familial intrahepatic cholestasis and benign recurrent intrahepatic cholestasis may be linked to intrahepatic cholestasis of pregnancy by alterations in the binding domains of liver receptors for DNA and oestrogens (<a href="./references#CD000493-bbs2-0086" title="LeevyCB , KoneruB , KleinKM . Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease. Gastroenterology1997;113(3):966-72.">Leevy 1997</a>). A higher than anticipated incidence of intrahepatic cholestasis of pregnancy has been found in the mothers of people with these two familial liver disorders (<a href="./references#CD000493-bbs2-0055" title="deSwietM . Medical Disorders in Obstetric Practice. Oxford: Blackwell Publishing, 2002.">de Swiet 2002</a>). </p> <p>The precise role of oestrogens is unknown, but their causal role is suggested by the appearance of intrahepatic cholestasis of pregnancy in the third trimester (when oestrogen concentrations are highest), the increased frequency in pregnancies with high oestrogen concentrations (e.g. multiple pregnancies) (<a href="./references#CD000493-bbs2-0064" title="GonzalezMC , ReyesH , ArreseM , FigueroaD , LorcaB , AndresenM , et al. Intrahepatic cholestasis of pregnancy in twin pregnancies. Journal of Hepatology1989;9(1):84-90. [MEDLINE: 2768798]">Gonzalez 1989</a>), and the resolution of symptoms following the cessation of pregnancy (<a href="./references#CD000493-bbs2-0063" title="GermainA , CarvajalJA , GlasinovicJC , KatoKS , WilliamsonC . Intrahepatic cholestasis of pregnancy: an intriguing pregnancy-specific disorder. Journal of the Society for Gynaecologic Investigation2002;9(1):10-4.">Germain 2002</a>). Women who develop intrahepatic cholestasis of pregnancy are at a higher risk of developing cholestasis with any oral contraceptive pill use. This also suggests that oestrogen may be an aetiological factor (<a href="./references#CD000493-bbs2-0055" title="deSwietM . Medical Disorders in Obstetric Practice. Oxford: Blackwell Publishing, 2002.">de Swiet 2002</a>). </p> <p>Similarly, the role of progesterone in intrahepatic cholestasis of pregnancy is unclear. While the total serum progesterone concentrations and the amount of progesterone excreted in urine are similar to normal pregnancies, large amounts of sulphated progesterone have been detected in the plasma and urine of women with intrahepatic cholestasis of pregnancy (<a href="./references#CD000493-bbs2-0092" title="MengLJ , ReyesH , PalmaJ , HernandezI , RibaltaJ , SjovallJ . Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. Journal of Hepatology1997;27(6):1029-40. [PMID: 9453429]">Meng 1997</a>). <i>In vitro</i> animal studies suggest that high concentrations of progesterone metabolites induce trans‐inhibition of the bile salt export pump (BSEP), and consequently interfere with bile acid secretion into bile. This leads to intracellular accumulation of bile acids, which disrupt mitochondrial function, and which may explain the role of progesterone metabolites in the aetiopathogenesis of intrahepatic cholestasis of pregnancy (<a href="./references#CD000493-bbs2-0118" title="VallejoM , BrizO , SerranoMA , MonteMJ , MarinJJ . Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. Journal of Hepatology2006;44(6):1150-7.">Vallejo 2006</a>). </p> <p>Seasonal variation in the prevalence of intrahepatic cholestasis of pregnancy suggests that environmental factors may have a role (<a href="./references#CD000493-bbs2-0105" title="ReyesH . Review: Intrahepatic cholestasis. A puzzling disorder of pregnancy. Gastroenterology and Hepatology1997;12(3):211-6.">Reyes 1997</a>). Pollutants in pesticides, erucic acid (a constituent of rape‐seed oil) and dietary deficiency of selenium have been suggested as possible environmental factors (<a href="./references#CD000493-bbs2-0106" title="RibaltaJ , ReyesH , HernandezI , FuentesO , BaezM , GonzalezM , et al. Can a selenium deficiency affect the pathogenesis of cholestasis in pregnancy?Gastroenterology and Hepatology1995;18(3):114-20.">Ribalta 1995</a>). </p> </section> <section id="CD000493-sec-0014"> <h4 class="title">Clinical features</h4> <p>Women present with pruritus without rash, characteristically after 30 weeks' gestation (<a href="./references#CD000493-bbs2-0074" title="KenyonAP , PiercyCN , GirlingJ , WilliamsonC , TribeRM , ShennanAP . Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG: an international journal of obstetrics and gynaecology2002;109(3):282-8.">Kenyon 2002</a>; <a href="./references#CD000493-bbs2-0104" title="ReyesH . The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterology Clinics of North America1992;21(4):905-21.">Reyes 1992</a>). Pruritus often worsens as the pregnancy progresses. Steatorrhoea and dark urine may occur. Jaundice is a rare symptom (<a href="./references#CD000493-bbs2-0055" title="deSwietM . Medical Disorders in Obstetric Practice. Oxford: Blackwell Publishing, 2002.">de Swiet 2002</a>). Increased rates of postpartum haemorrhage have been postulated to be due to vitamin K deficiency (<a href="./references#CD000493-bbs2-0070" title="JohnstonWG , BaskettTF . Obstetric cholestasis; a 14 year review. Journal of Obstetrics and Gynecology1979;133(3):299-301.">Johnston 1979</a>; <a href="./references#CD000493-bbs2-0101" title="ReidR , IveyKJ , RencoretRH , StoreyB . Fetal complications of obstetric cholestasis. British Medical Journal1976;1(6014):870-2.">Reid 1976</a>; <a href="./references#CD000493-bbs2-0104" title="ReyesH . The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterology Clinics of North America1992;21(4):905-21.">Reyes 1992</a>). One non‐randomised study reported a higher rate of postpartum haemorrhage in women who had not taken vitamin K compared with those who had (<a href="./references#CD000493-bbs2-0074" title="KenyonAP , PiercyCN , GirlingJ , WilliamsonC , TribeRM , ShennanAP . Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG: an international journal of obstetrics and gynaecology2002;109(3):282-8.">Kenyon 2002</a>). Gallstones may be present more often in affected women (<a href="./references#CD000493-bbs2-0076" title="KirkenenP , YlostaloP , HeikkinenJ , MaentaustaO . Gallbladder function and maternal acids in intrahepatic cholestasis of pregnancy. European Journal of Obstetrics, Gynecology, and Reproductive Biology1984;18(1-2):29-34.">Kirkinen 1984</a>; <a href="./references#CD000493-bbs2-0110" title="RopponenA , SundR , RiikonenS , Ylikorkala, AittomakiK . Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology2006;43(4):723-8.">Ropponen 2006</a>). Women with hepatitis C infection have a higher incidence of intrahepatic cholestasis of pregnancy (<a href="./references#CD000493-bbs2-0087" title="LocatelliA , RoncagliaN , ArreghiniA , BelliniP , VerganiP , GhidiniA . Hepatitis C virus infection is associated with a higher incidence of cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1999;106(5):498-500.">Locatelli 1999</a>; <a href="./references#CD000493-bbs2-0098" title="PaternosterDM , FabrisF , PalùG , SantarossaC , BraccianteR , SnijdersD , et al. Intra-hepatic cholestasis of pregnancy in hepatitis C virus infection. Acta Obstetricia et Gynecologica Scandinavica2002;81(2):99-103.">Paternoster 2002</a>). Pre‐eclampsia and gestational diabetes are seen more commonly in women with intrahepatic cholestasis of pregnancy (<a href="./references#CD000493-bbs2-0089" title="MaratheJA , LimWH , MetzMP , ScheilW , DekkerGA , HagueWM . A retrospective cohort review of intrahepatic cholestasis of pregnancy in a South Australian population. European Journal of Obstetrics, Gynecology, and Reproductive Biology2017;218:33-8. [PMID: 28926728]">Marathe 2017</a>; <a href="./references#CD000493-bbs2-0091" title="MartineauM , RakerC , PowrieR , WilliamsonC . Intrahepatic cholestasis of pregnancy is associated with an increased risk of gestational diabetes. European Journal of Obstetrics, Gynecology, and Reproductive Biology2014;176:80-5. [PMID: 24462052]">Martineau 2014</a>; <a href="./references#CD000493-bbs2-0120" title="Wikstrom ShemerE , MarschallHU , LudvigssonJF , StephanssonO . Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. BJOG: an international journal of obstetrics and gynaecology2013;120(6):717-23. [PMID: 23418899]">Wikstrom 2013</a>). </p> </section> <section id="CD000493-sec-0015"> <h4 class="title">Investigations</h4> <p>The most specific laboratory test for intrahepatic cholestasis of pregnancy is measurement of plasma or serum concentration of total bile acids, which will usually include cholic or chenodeoxycholic acid: values may be 10 to 100 times those found in healthy pregnant women (<a href="./references#CD000493-bbs2-0042" title="BacqY , SapeyT , BrechotMC , PierreF , FignonA , DuboisF . Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology1997;26(2):358-64.">Bacq 1997</a>; <a href="./references#CD000493-bbs2-0065" title="HeikkinenJ , MaentaustaO , YlostaloP , JanneO . Changes in serum bile acid concentrations during normal pregnancy, in patients with intrahepatic cholestasis of pregnancy and in pregnant women with itching. British Journal of Obstetrics and Gynaecology1981;88(3):240-5.">Heikkinen 1981</a>). Increases in serum transaminases are also common (<a href="./references#CD000493-bbs2-0105" title="ReyesH . Review: Intrahepatic cholestasis. A puzzling disorder of pregnancy. Gastroenterology and Hepatology1997;12(3):211-6.">Reyes 1997</a>). Unlike in other cholestatic diseases, increases in serum gamma glutamyl transferase (GGT) are less common (<a href="./references#CD000493-bbs2-0119" title="WalkerIA , Nelson-PiercyC , WilliamsonC . Role of bile acid measurement in pregnancy. Annals of Clinical Biochemistry2002;39(Part 2):105-13.">Walker 2002</a>). If there is clinical uncertainty about the diagnosis of ICP, particularly with asymptomatic clinical presentation, then other investigations should be considered. Upper abdominal ultrasound can be performed to exclude gallbladder disease, duct dilatation and other liver pathology. Serology for hepatitis A, B, C, Epstein Barr virus (EBV) and cytomegalovirus (CMV) can help to exclude viral pathology, while an autoimmune screen including anti‐smooth muscle, liver‐kidney microsomal (LKM) and antimitochondrial antibodies can help to identify women with chronic active hepatitis or primary biliary cholangitis (<a href="./references#CD000493-bbs2-0042" title="BacqY , SapeyT , BrechotMC , PierreF , FignonA , DuboisF . Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology1997;26(2):358-64.">Bacq 1997</a>; <a href="./references#CD000493-bbs2-0066" title="HeinonenS , KirkinenP . Pregnancy outcome with intrahepatic cholestasis. Obstetrics and Gynecology1999;94(2):189-93.">Heinonen 1999</a>; <a href="./references#CD000493-bbs2-0075" title="KenyonAP , GirlingJC . Obstetric cholestasis. Progress in Obstetrics and Gynaecology2005;16:37-56.">Kenyon 2005</a>). There is no evidence that routine testing of all women who present with ICP is needed (<a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>). </p> </section> <section id="CD000493-sec-0016"> <h4 class="title">Fetal effects</h4> <p>The implication of excess circulating maternal serum bile acids for the fetus is not completely understood. Increased rates of fetal complications, perinatal mortality rates, stillbirths, low birthweight, preterm labour and birth, and fetal distress in labour have been linked with the condition (<a href="./references#CD000493-bbs2-0040" title="AlsulymanOM , OuzounianJG , Ames-CastroM , GoodwinTM . Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. American Journal of Obstetrics and Gynecology1996;175(4 Part 1):957-60. [MEDLINE: 8885754]">Alsulyman 1996</a>; <a href="./references#CD000493-bbs2-0054" title="DaviesMH , da SilvaRC , JonesSR , WeaverJB , EliasE . Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Gut1995;37(4):580-4. [MEDLINE: 7489950]">Davies 1995</a>; <a href="./references#CD000493-bbs2-0060" title="FiskNM , StoreyGN . Fetal outcome in obstetric cholestasis. British Journal of Obstetrics and Gynaecology1988;95(11):1137-43.">Fisk 1988</a>; <a href="./references#CD000493-bbs2-0061" title="GaudetR , MervielP , BerkaneN , SchouppeS , CochetonJJ , UzanS . Fetal impact of cholestasis of pregnancy: experience at Tenon Hospital and literature review. Fetal Diagnosis Therapy2000;15(4):191-7.">Gaudet 2000</a>; <a href="./references#CD000493-bbs2-0069" title="JiangZH , QiuZD , LiuWW , LiuYH , WangQN , MiaoHZ , et al. Intrahepatic cholestasis of pregnancy and its complications. Analysis of 100 cases in Chongqing area. Chinese Medical Journal1986;99(12):957-60. [MEDLINE: 3105974]">Jiang 1986</a>; <a href="./references#CD000493-bbs2-0070" title="JohnstonWG , BaskettTF . Obstetric cholestasis; a 14 year review. Journal of Obstetrics and Gynecology1979;133(3):299-301.">Johnston 1979</a>; <a href="./references#CD000493-bbs2-0081" title="LaatikainenT , IkonenE . Fetal prognosis in obstetric hepatosis. Annales Chirurgiae et Gynaecologiae Fenniae1975;64(3):155-64. [MEDLINE: 1217841]">Laatikainen 1975</a>; <a href="./references#CD000493-bbs2-0097" title="OvadiaC , SeedPT , SklavounosA , GeenesV , Di IllioC , ChambersJ , et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet2019;393(10174):899-909.">Ovadia 2019</a>; <a href="./references#CD000493-bbs2-0101" title="ReidR , IveyKJ , RencoretRH , StoreyB . Fetal complications of obstetric cholestasis. British Medical Journal1976;1(6014):870-2.">Reid 1976</a>; <a href="./references#CD000493-bbs2-0107" title="RiosecoAJ , IvankovicMB , AlejandroM , HamedF , KatoSR , ParerJT , et al. Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome. American Journal of Obstetrics and Gynecology1994;170(3):890-5.">Rioseco 1994</a>; <a href="./references#CD000493-bbs2-0111" title="RoszkowskiI , Pisarek-MiedzinskaD . Jaundice in pregnancy. II. Clinical course of pregnancy and delivery and condition of neonate. American Journal of Obstetrics and Gynecology1968;101(4):500-3.">Roszkowski 1968</a>; <a href="./references#CD000493-bbs2-0122" title="WilliamsonC , HemsLM , GoulisDG , WalkerI , ChambersJ , DonaldsonO , et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG: an international journal of obstetrics and gynaecology2004;111(7):676-81. [MEDLINE: 15198757]">Williamson 2004</a>; <a href="./references#CD000493-bbs2-0123" title="WilsonBR , HaverkampAD . Cholestatic jaundice of pregnancy: new perspectives. Obstetrics and Gynecology1979;54(5):650-2. [MEDLINE: 503397]">Wilson 1979</a>; <a href="./references#CD000493-bbs2-0124" title="YlostaloP , YlikorkalaO . Hepatosis of pregnancy. A clinical study of 107 patients. Annales Chirurgiae et Gynaecologiae Fenniae1975;64:128-34. [MEDLINE: 1137335]">Ylostalo 1975</a>). There is evidence to suggest an increased incidence of meconium‐stained amniotic fluid in women with intrahepatic cholestasis of pregnancy (<a href="./references#CD000493-bbs2-0100" title="Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis (Guideline No. 43). London: RCOG, 20.">RCOG 2011</a>), and it is more common in those with serum bile acid concentrations greater than 40 µmol/L (<a href="./references#CD000493-bbs2-0084" title="LeeRH , KwokKM , InglesS , WilsonML , MullinP , IncerpiM , et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. American Journal of Perinatology2008;25(6):341-5.">Lee 2008</a>). No specific fetal monitoring, such as cardiotocography (CTG), ultrasound or amniocentesis for meconium presence, has been found to be beneficial or accurate in predicting an adverse outcome in intrahepatic cholestasis of pregnancy (<a href="./references#CD000493-bbs2-0100" title="Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis (Guideline No. 43). London: RCOG, 20.">RCOG 2011</a>). Possible mechanisms for fetal compromise that have been suggested include a toxic effect of bile acids on the fetal myocardium, leading to cardiac dysrhythmia and acute anoxia, as demonstrated in neonatal rat cardiomyocytes (<a href="./references#CD000493-bbs2-0121" title="WilliamsonC , GorelikJ , EatonBM , LabM , KorchevY , deSwietM . The bile acid taurocholate impair rat cardiomyocyte function: a proposed mechanism for intra-uterine fetal death in obstetric cholestasis. Clinical Science2001;100(4):363-9.">Williamson 2001</a>). It has been hypothesised that high bile acid concentrations in the mother may cause bile acid pneumonia in the newborn (<a href="./references#CD000493-bbs2-0125" title="ZeccaE , De LucaD , MarrasM , CarusoA , TommasoB , RomagnoliC . Intrahepatic cholestasis of pregnancy and neonatal respiratory distress syndrome. Pediatrics2006;117(5):1669-72.">Zecca 2006</a>; <a href="./references#CD000493-bbs2-0126" title="ZeccaE , De LucaD , BaroniS , VentoG , TiberiE , RomagnoliC . Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study. Pediatrics2008;121(1):e146-e149.">Zecca 2008</a>). </p> </section> </section> <section id="CD000493-sec-0017"> <h3 class="title" id="CD000493-sec-0017">Description of the intervention</h3> <p>All interventions considered in this review are classified as 'pharmacological interventions', i.e. treatments that use medicines or drugs, and include topical preparations and Chinese herbal medicines. </p> <p>Topical emollients may provide temporary relief of pruritus for some women, and are widely used (<a href="./references#CD000493-bbs2-0100" title="Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis (Guideline No. 43). London: RCOG, 20.">RCOG 2011</a>). Oral antihistamine medications are sometimes prescribed to provide symptom relief, although their role in reducing itching in intrahepatic cholestasis of pregnancy has not been substantiated, and some of the impact may be related to the sedative side‐effects. In the UK, USA and Australia, chlorpheniramine, hydroxyzine, diphenhydramine, cetirizine and promethazine are commonly used as first‐line agents to treat pruritus in women with ICP. Other treatments, aimed at decreasing bile acid production (dexamethasone and phenobarbitone), are now rarely used in UK and Australian practice. </p> <p>Some agents have been used that bind bile acids in the intestine, facilitating their elimination and preventing enterohepatic recirculation (activated charcoal, guar gum, cholestyramine). Agents binding bile acids in this way have the potential for adverse effects for mothers due to the depletion of vitamin K (<a href="./references#CD000493-bbs2-0048" title="BriggsGG , FreemanRK , YaffeSJ . Drugs in Pregnancy and Lactation. 6th edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001.">Briggs 2001</a>). </p> <p>Other therapies such as ursodeoxycholic acid (UDCA) and S‐adenosylmethionine (SAMe) may detoxify bile acids, or change their solubility, thereby allowing increased choleresis and potentially reducing their adverse cellular effects. </p> <p>Rifampicin has been used outside of pregnancy in the treatment of several cholestatic liver diseases. The mechanisms of its actions may be complementary to those of UDCA and include enhanced bile acid detoxification and elimination (<a href="./references#CD000493-bbs2-0090" title="MarschallHU , WagnerM , ZollnerG , FickertP , DiczfalusyU , GumholdJ , et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology2005;129(2):476-85. [PMID: 16083704]">Marschall 2005</a>). </p> <p>Yinchenghao decoction (YCHD), Salvia, Danxioling and Yiganling are used in Chinese medicine for their hepato‐protective properties. There is little information available on these products. </p> <p>Side effects (as well as benefits) for the fetus potentially exist for dexamethasone, phenobarbitone, rifampicin, SAMe and UDCA, since they all cross the placenta. </p> </section> <section id="CD000493-sec-0018"> <h3 class="title" id="CD000493-sec-0018">How the intervention might work</h3> <p>The efficacy of topical emollients has not been tested in clinical trials but they seem to provide temporary relief from pruritus in some women and are safe in pregnancy (<a href="./references#CD000493-bbs2-0100" title="Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis (Guideline No. 43). London: RCOG, 20.">RCOG 2011</a>). Calamine lotion contains zinc oxide (ZnO) and 0.5% iron oxide (Fe<sub>2</sub>O<sub>3</sub>) and has antipruritic and antiseptic properties. One to two per cent menthol in aqueous cream affects A delta sensory nerve fibres and suppresses histamine‐induced itching (<a href="./references#CD000493-bbs2-0045" title="BernhardJD . General principles, overview and miscellaneous treatments of itching. In: Itch Mechanisms and Management of Pruritus. New York: McGraw-Hill, 1994:367-81.">Bernhard 1994</a>; <a href="./references#CD000493-bbs2-0050" title="BrommaB , SchareinE , DarsowU , RingJ . Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neuroscience Letters1995;187(3):157-60.">Bromma 1995</a>). Diprobase contains liquid paraffin, white soft paraffin, cetomacrogol and cetostearyl alcohol. The principle behind its use is to provide symptomatic relief from itching due to its moisturising properties. Balneum Plus cream contains urea and lauromacrogols; the hydrophilic properties of urea hydrate the skin and the local anaesthetic properties of lauromacrogols cause a soothing effect. </p> <p>Chlorpheniramine is a first‐generation alkylamine antihistamine. Its use, and that of other H1‐antagonist antihistamines, in intrahepatic cholestasis of pregnancy has not been tested in a clinical trial but it seems to provide symptomatic relief from itching in some women. It can cause sedation but is otherwise safe in pregnancy. </p> <p>Dexamethasone is a glucocorticoid which decreases the synthesis of fetal and maternal adrenocorticotrophin hormone (ACTH). It also reduces production and secretion of the oestrogen precursors, dehydroepiandrosterone (DHEA) and DHEA sulphate, from both maternal and fetal adrenal glands (<a href="./references#CD000493-bbs2-0072" title="KauppilaA , TuimalaR , YlikorkalaO , ReinilaM , YlostaloP . Placental steroid synthesis from DHEAS during dexamethasone therapy. Obstetrics and Gynecology1979;54(1):39-41.">Kauppila 1979</a>; <a href="./references#CD000493-bbs2-0115" title="SimmerHH , FranklandM , GreipelM . On the regulation of fetal and maternal 16-a-hydroxydehydroepiandrosterone and its sulphates by cortisol and ACTH in human pregnancy at term. American Journal of Obstetrics and Gynecology1975;121(5):646-52.">Simmer 1975</a>). More than 50% of oestrogen in the maternal circulation is derived from the feto‐placental unit. Reduction of maternal oestrogen concentrations may be a mechanism by which it may improve cholestasis (<a href="./references#CD000493-bbs2-0056" title="DiacM , KenyonA , Nelson-PiercyC , GirlingJ , ChengF , TribeRM , et al. Dexamethasone in the treatment of obstetric cholestasis: a case series. Journal of Obstetrics and Gynaecology2006;26(2):110-4.">Diac 2006</a>). </p> <p>The role of phenobarbitone in cholestasis was first demonstrated in 1968 (<a href="./references#CD000493-bbs2-0053" title="CunninghamMD , KelleyLR , PetersER . Phenobarbitone in cholestasis. Lancet1968;291(7551):1089.">Cunningham 1968</a>). Animal models suggest that phenobarbitone increases the excretion of bile salts into the biliary tree and enhances bile flow (<a href="./references#CD000493-bbs2-0077" title="KlaasenCD . Effects of phenobarbital on the plasma disappearance and biliary excretion of drugs in rats. Journal of Pharmacology and Experimental Therapeutics1970;175(2):289-300.">Klaasen 1970</a>; <a href="./references#CD000493-bbs2-0108" title="RobinsonSH , YannoniC , NagasawaS . Bilirubin excretion in rats with normal and impaired bilirubin conjugation: effect of Phenobarbital. Journal of Clinical Investigation1971;50(12):2602-13.">Robinson 1971</a>). </p> <p>Activated charcoal is a highly porous carbon compound. It is widely used to treat acute poisoning following oral ingestion, where it binds to the toxin and prevents its absorption from the stomach and intestine. It can effectively adsorb bile salts in vitro (<a href="./references#CD000493-bbs2-0079" title="KrasopoulosJC , De BariVA , NeedleMA . The adsorption of bile salts on activated carbon. Lipids1980;15(5):365-70.">Krasopoulos 1980</a>). </p> <p>Guar gum is a viscous polysaccharide obtained from guar beans, which helps to hold plant cells together. Its main use is in the food industry where it is used to thicken or add texture to foods and drinks (<a href="./references#CD000493-bbs2-0068" title="InselP , RossD , McMahonK , BernsteinM . Nutrition. 4th edition. London, UK: Jones and Barlett, 2010.">Insel 2010</a>). It is also used to add thickness in lotions and creams, and to bind ingredients together in tablets, and was widely used as an appetite suppressor in weight loss formulations in the past. Guar gums bind the bile acids to the intestinal contents, which are then expelled from the body (<a href="./references#CD000493-bbs2-0095" title="MorganLM , TredgerJA , ShavilaY , TravisJS , WrightJ . The effect of non-starch polysaccharide supplementation on circulating bile acids, hormone and metabolite levels following a fat meal in human subjects. British Journal of Nutrition1993;70(2):491-501.">Morgan 1993</a>). </p> <p>Cholestyramine is a resin that binds to bile acids in the intestine and prevents their reabsorption. Consequently, it may interfere with the absorption of fat‐soluble vitamins, including vitamin K, which is essential for blood coagulation. This may increase the risk of postpartum haemorrhage in the mother and intracranial haemorrhage in the fetus (<a href="./references#CD000493-bbs2-0112" title="SadlerLC , LaneM , NorthR . Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. BJOG: an international journal of obstetrics and gynaecology1995;102(2):169-70.">Sadler 1995</a>). </p> <p>Rifampicin (RIF) is a semisynthetic antibiotic with a wide range of antimicrobial activity, including for treatment of tuberculosis, where it is a first‐line agent including for treatment of pregnant women (<a href="./references#CD000493-bbs2-0088" title="LotoOM , AwowoleI . Tuberculosis in pregnancy: a review. Journal of Pregnancy2012;2012:379271. [PMID: 22132339]">Loto 2012</a>). It has also been shown to have the capacity to reduce serum bile acids in the management of cholestasis outside of pregnancy (<a href="./references#CD000493-bbs2-0090" title="MarschallHU , WagnerM , ZollnerG , FickertP , DiczfalusyU , GumholdJ , et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology2005;129(2):476-85. [PMID: 16083704]">Marschall 2005</a>). A systematic review of pharmacological interventions for pruritus in palliative care showed that, in people with cholestatic pruritus, data favoured the use of RIF, with a low incidence of adverse events when compared with placebo (<a href="./references#CD000493-bbs2-0114" title="SiemensW , XanderC , MeerpohlJJ , BurohS , AntesG , SchwarzerG , et al. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD008320. [DOI: 10.1002/14651858.CD008320.pub3]">Siemens 2016</a>). There have been no trials comparing UDCA and rifampicin in the treatment of cholestatic pruritus, nor have there been any completed trials in intrahepatic cholestasis of pregnancy, although there have been a small number of case reports and one small series (<a href="./references#CD000493-bbs2-0062" title="GeenesV , ChambersJ , KhuranaR , ShemerEW , SiaW , MandairD , et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. European Journal of Obstetrics, Gynecology, and Reproductive Biology2015;189:59-63. [PMID: 25864112]">Geenes 2015</a>). </p> <p>S‐adenosylmethionine (SAMe) is produced from methionine and adenosine triphosphate (ATP) in all mammalian cells. The liver is the principal site where it is produced and metabolised (<a href="./references#CD000493-bbs2-0052" title="CantoniGL . The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate. Journal of the American Chemical Society1952;74(11):2942-3.">Cantoni 1952</a>). It is an important methyl group donor and plays a crucial role in the biosynthesis of phospholipids, which are important for maintaining the fluidity of hepatic cell membranes and excretion of oestrogen metabolites (<a href="./references#CD000493-bbs2-0047" title="BoelsterliUA , RakhitG , BalazsT . Modulation by S-adenosyl-L-methionine of hepatic Na+,K+-ATPase, membrane fluidity, and bile flow in rats with ethinyl estradiol-induced cholestasis. Hepatology1983;3(1):12-7.">Boelsterli 1983</a>). Interference with hepatic SAMe biosynthesis may cause and predispose hepatocytes to injury. Experiments on rat models indicate that SAMe can reverse cholestasis (<a href="./references#CD000493-bbs2-0117" title="StramentinoliG , Di PadovaC , GualanoM , RovagnatiP , Galli-KienleM . Ethynylestradiol-induced impairment of bile secretion in the rat: protective effects of S-adenosyl-L-methionine and its implication in estrogen metabolism. Gastroenterology1981;80(1):154-8.">Stramentinoli 1981</a>). The exact mechanism of action remains unclear. </p> <p>Ursodeoxycholic acid (UDCA) is a naturally‐occurring hydrophilic bile acid. Studies suggest that UDCA displaces endogenous hydrophobic detergent‐like toxic bile acids in cholestatic disorders without disrupting the bile acid pool (<a href="./references#CD000493-bbs2-0116" title="StiehlA , BenzC , SauerP . Mechanism of hepatoprotective action of bile salts in liver disease. Gastroenterology Clinics of North America1999;28(1):195-209.">Stiehl 1999</a>). UDCA has been credited with cytoprotective and anti‐apoptotic properties (<a href="./references#CD000493-bbs2-0094" title="MitsuyoshiH , NakashimaT , SumidaY , YohT , NakajimaY , IshikawaH , et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochemical and Biophysical Research Communications1999;263(2):537-42.">Mitsuyoshi 1999</a>; <a href="./references#CD000493-bbs2-0109" title="RodriguesCM , FanG , MaX , KrenBT , SteerCJ . A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. Journal of Clinical Investigation1998;101(12):2790-9.">Rodrigues 1998</a>). Animal studies have shown that UDCA improves hepatocellular and cholangiocellular biliary secretion in cholestatic disorders by post‐transcriptional regulation of the apical transporters BSEP and multidrug resistance protein 2 (MRP2) (<a href="./references#CD000493-bbs2-0046" title="BeuersU , BilzerM , ChittattuA , Kullak-UblickGA , KepplerD , PaumgartnerG , et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology2001;33(5):1206-16.">Beuers 2001</a>). Women with intrahepatic cholestasis of pregnancy treated with UDCA have reduced cord‐blood bile acid concentrations (<a href="./references#CD000493-bbs2-0049" title="BritesD . Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Annals of Hepatology2002;1(1):20-8. [PMID: 15114292]">Brites 2002</a>). This may be due to up‐regulation of the expression of placental MRP2 (<a href="./references#CD000493-bbs2-0041" title="AzzaroliF , MennoneA , FelettiV , SimoniP , BaglivoE , MontagnaniM , et al. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. Alimentary Pharmacology and Therapeutics2007;26(8):1139-46.">Azzaroli 2007</a>). </p> <p>Yinchenghao decoction (YCHD) is extracted from three different herbs: <i>Artemisia capillaries</i> , <i>Gardenia jasminoides</i> Ellis and <i>Rheum officinale</i> Baill. It was invented two millennia ago and has been used in Chinese medicine to treat a wide range of liver disorders. Down‐regulation of the production of pro‐inflammatory cytokine tumour necrosis factor (TNF) by inhibition of NF‐kappaB activation (<a href="./references#CD000493-bbs2-0051" title="CaiH , SongYH , XiaWJ , JinMW . Aqueous extract of Yin-Chen-Hao decoction, a traditional Chinese prescription, exerts protective effects on concanavalin A-induced hepatitis in mice through inhibition of NF-k B. Journal of Pharmacy and Pharmacology2006;58(5):677-84.">Cai 2006</a>), an antifibrotic action, in part due to the inhibitory action on extracellular matrix (ECM) gene expression (<a href="./references#CD000493-bbs2-0085" title="LeeTY , ChangHH , KuoJJ , ShenJJ . Changes of hepatic proteome in bile duct ligated rats with hepatic fibrosis following treatment with Yin-Chen-Hao-Tang. International Journal of Molecular Medicine2009;23(4):477-84.">Lee 2009</a>), and decreased tumour growth factor 1 (TGF‐1) mRNA expression and inhibition of lipid peroxidation with reduced hepatic collagen accumulation (<a href="./references#CD000493-bbs2-0083" title="LeeTY , ChangaHH , ChenJH , HsuehML , KuoJJ . Herb medicine Yin-Chen-Hao-Tang ameliorates hepatic fibrosis in bile duct ligation rats. Journal of Ethnopharmacology2007;109(2):318-24.">Lee 2007</a>) have all been postulated as possible mechanisms for its hepato‐protective properties. </p> <p><i>Salvia miltiorrhiza</i>, also known as red sage or Danshen, a perennial plant in the genus Salvia of the mint family, is a traditional Chinese medicine. It has been used for more than 2000 years to improve blood circulation and for the treatment of chronic hepatitis and liver fibrosis (<a href="./references#CD000493-bbs2-0096" title="OhSH , NanJX , SohnD , KimYC , LeeBH . Salvia miltiorrhiza inhibits biliary obstruction-induced hepatocyte apoptosis by cytoplasmic sequestration of p53. Toxicology and Applied Pharmacology2002;182(1):27-33.">Oh 2002</a>). Its hepato‐protective effects are believed to be a result of inhibition of hepatocellular apoptosis induced by bile salts (<a href="./references#CD000493-bbs2-0096" title="OhSH , NanJX , SohnD , KimYC , LeeBH . Salvia miltiorrhiza inhibits biliary obstruction-induced hepatocyte apoptosis by cytoplasmic sequestration of p53. Toxicology and Applied Pharmacology2002;182(1):27-33.">Oh 2002</a>). </p> </section> <section id="CD000493-sec-0019"> <h3 class="title" id="CD000493-sec-0019">Why it is important to do this review</h3> <p>This is an update of a Cochrane Review first published in 2001 (<a href="./references#CD000493-bbs2-0128" title="BurrowsRF , ClavisiO , BurrowsE . Interventions for treating cholestasis in pregnancy. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD000493. [DOI: 10.1002/14651858.CD000493]">Burrows 2001</a>) and updated in 2013 (<a href="./references#CD000493-bbs2-0129" title="GurungV , StokesM , MiddletonP , MilanSJ , HagueW , ThorntonJG . Interventions for treating cholestasis in pregnancy. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD000493. [DOI: 10.1002/14651858.CD000493.pub2]">Gurung 2013</a>), which concluded that there was insufficient evidence for any of the treatments for intrahepatic cholestasis of pregnancy so far evaluated in randomised controlled trials. None was found to be consistently effective in resolving maternal pruritus. Since 2013 new trials have been published, including one comparing UDCA with placebo which is larger than all previous trials combined. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000493-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000493-sec-0020"></div> <p>To assess the effects of pharmacological interventions to treat women with intrahepatic cholestasis of pregnancy, on maternal, fetal and neonatal outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000493-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000493-sec-0021"></div> <section id="CD000493-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000493-sec-0023"> <h4 class="title">Types of studies</h4> <p>Randomised or quasi‐randomised controlled trials, including cluster‐randomised trials and trials published in abstract form only. </p> </section> <section id="CD000493-sec-0024"> <h4 class="title">Types of participants</h4> <p>Women stated to have a diagnosis of intrahepatic cholestasis of pregnancy (ICP).</p> </section> <section id="CD000493-sec-0025"> <h4 class="title">Types of interventions</h4> <p>Pharmacological interventions used to treat intrahepatic cholestasis of pregnancy and its symptoms, compared with placebo or no treatment or another intervention. We include pharmacological interventions or treatments that use medicines or drugs in this review, and include topical preparations and Chinese herbal medicines. </p> <p>Physical treatments, such as induction of labour, were in the last version of this review (<a href="./references#CD000493-bbs2-0129" title="GurungV , StokesM , MiddletonP , MilanSJ , HagueW , ThorntonJG . Interventions for treating cholestasis in pregnancy. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD000493. [DOI: 10.1002/14651858.CD000493.pub2]">Gurung 2013</a>). We have removed them from this version, and may cover them in a separate review (Timed delivery for treating intrahepatic cholestasis of pregnancy). </p> </section> <section id="CD000493-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD000493-sec-0027"> <h5 class="title">Primary outcomes</h5> <section id="CD000493-sec-0028"> <h6 class="title">Maternal</h6> <p> <ul id="CD000493-list-0001"> <li> <p>Pruritus (scores, change in score, improvement)</p> </li> </ul> </p> </section> <section id="CD000493-sec-0029"> <h6 class="title">Fetal/neonatal</h6> <p> <ul id="CD000493-list-0002"> <li> <p>Stillbirths or neonatal deaths</p> </li> <li> <p>Fetal distress/asphyxial events</p> </li> </ul> </p> </section> </section> <section id="CD000493-sec-0030"> <h5 class="title">Secondary outcomes</h5> <section id="CD000493-sec-0031"> <h6 class="title">Maternal</h6> <p> <ul id="CD000493-list-0003"> <li> <p>Liver function, as measured by serum bile acid and serum ALT</p> </li> <li> <p>Caesarean section</p> </li> <li> <p>Postpartum haemorrhage</p> </li> <li> <p>Adverse effects of medication</p> </li> </ul> </p> </section> <section id="CD000493-sec-0032"> <h6 class="title">Fetal/neonatal</h6> <p> <ul id="CD000493-list-0004"> <li> <p>Meconium‐stained liquor</p> </li> <li> <p>Mean gestational age at birth</p> </li> <li> <p>Spontaneous birth at less than 37 weeks</p> </li> <li> <p>Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</p> </li> <li> <p>Admission to neonatal intensive care unit</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD000493-sec-0033"> <h3 class="title">Search methods for identification of studies</h3> <p>The following Methods section of this review is based on a standard template used by Cochrane Pregnancy and Childbirth. </p> <section id="CD000493-sec-0034"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched Cochrane Pregnancy and Childbirth’s Trials Register by contacting their Information Specialist (13 December 2019).. </p> <p>The Register is a database containing over 25,000 reports of controlled trials in the field of pregnancy and childbirth. It represents over 30 years of searching. For full current search methods used to populate Pregnancy and Childbirth’s Trials Register including the detailed search strategies for CENTRAL, MEDLINE, Embase and CINAHL; the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service, please follow this <a href="https://pregnancy.cochrane.org/pregnancy-and-childbirth-groups-trials-register" target="_blank">link</a>. </p> <p>Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is maintained by their Information Specialist and contains trials identified from: </p> <p> <ol id="CD000493-list-0005"> <li> <p>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>weekly searches of MEDLINE (Ovid);</p> </li> <li> <p>weekly searches of Embase (Ovid);</p> </li> <li> <p>monthly searches of CINAHL (EBSCO);</p> </li> <li> <p>handsearches of 30 journals and the proceedings of major conferences;</p> </li> <li> <p>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. </p> </li> </ol> </p> <p>Search results are screened by two people and the full text of all relevant trial reports identified through the searching activities described above is reviewed. Based on the intervention described, each trial report is assigned a number that corresponds to a specific Pregnancy and Childbirth review topic (or topics), and is then added to the Register. The Information Specialist searches the Register for each review using this topic number rather than keywords. This results in a more specific search set that has been fully accounted for in the relevant review sections (<a href="./references#CD000493-bbs1-0001" title="">Included studies</a>; <a href="./references#CD000493-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD000493-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD000493-bbs1-0004" title="">Ongoing studies</a>). </p> <p>In addition, we searched <a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) for unpublished, planned and ongoing trial reports (13 December 2019), using the search methods detailed in <a href="./appendices#CD000493-sec-0297">Appendix 1</a>. </p> </section> <section id="CD000493-sec-0035"> <h4 class="title">Searching other resources</h4> <p>We searched the reference lists of retrieved studies.</p> <p>We did not apply any language or date restrictions.</p> </section> </section> <section id="CD000493-sec-0036"> <h3 class="title" id="CD000493-sec-0036">Data collection and analysis</h3> <p>For the methods used when assessing the trials identified in the previous version of this review, <i>see</i><a href="./references#CD000493-bbs2-0129" title="GurungV , StokesM , MiddletonP , MilanSJ , HagueW , ThorntonJG . Interventions for treating cholestasis in pregnancy. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD000493. [DOI: 10.1002/14651858.CD000493.pub2]">Gurung 2013</a>. For this update we used the following methods when assessing the trials identified by the updated search. </p> <section id="CD000493-sec-0037"> <h4 class="title">Selection of studies</h4> <p>Two review authors (Kate Walker (KW) and Jim Thornton (JT)) independently assessed all the studies identified as a result of the search strategy for potential inclusion. There were no disagreements. We considered studies presented only as abstracts for inclusion on the same basis as studies published in full. </p> </section> <section id="CD000493-sec-0038"> <h4 class="title">Data extraction and management</h4> <p>JT designed a form to extract data. For eligible studies, KW and JT extracted the data using the agreed form. We resolved discrepancies through discussion or by consulting the other review authors (Philippa Middleton (PM), William Hague (WH), Lucy Chappell (LC)). KW entered data into Review Manager 5 software (<a href="./references#CD000493-bbs2-0102" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) and JT checked for accuracy. </p> <p>When information on any of the above was unclear, we attempted to contact authors of the original reports to provide further details. </p> </section> <section id="CD000493-sec-0039"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>KW and JT independently assessed risks of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000493-bbs2-0067" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). The two trials for which JT and LC had a conflict of interest (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>) were assessed by KW and PM. We resolved any disagreement by discussion or by consulting the other assessors. </p> <section id="CD000493-sec-0040"> <h5 class="title">(1) Random sequence generation (checking for possible selection bias)</h5> <p>We describe for each included study whether the method used to generate the allocation sequence was described in sufficient detail to allow an assessment of whether it produced comparable groups. </p> <p>We assessed the method as:</p> <p> <ul id="CD000493-list-0006"> <li> <p>low risk of bias (any truly random process, e.g. random‐number table; computer random‐number generator); </p> </li> <li> <p>high risk of bias (any non‐random process, e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD000493-sec-0041"> <h5 class="title"> (2) Allocation concealment (checking for possible selection bias)</h5> <p>We describe for each included study whether the method used to conceal the allocation sequence and determine whether intervention allocation could have been foreseen in advance of assignment, or during recruitment, or changed after assignment. </p> <p>We assessed the methods as:</p> <p> <ul id="CD000493-list-0007"> <li> <p>low risk of bias (e.g. telephone or central randomisation; consecutively‐numbered sealed opaque envelopes); </p> </li> <li> <p>high risk of bias (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk of bias.   </p> </li> </ul> </p> </section> <section id="CD000493-sec-0042"> <h5 class="title">(3.1) Blinding of participants and personnel (checking for possible performance bias)</h5> <p>We describe for each included study the methods used, if any, to blind study participants and research personnel from knowledge of which intervention a participant received. We considered studies to be at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed the methods as:</p> <p> <ul id="CD000493-list-0008"> <li> <p>low, high or unclear risk of bias for participants;</p> </li> <li> <p>low, high or unclear risk of bias for research personnel.</p> </li> </ul> </p> </section> <section id="CD000493-sec-0043"> <h5 class="title">(3.2) Blinding of outcome assessment (checking for possible detection bias)</h5> <p>We describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. </p> <p>We assessed methods used to blind outcome assessment as:</p> <p> <ul id="CD000493-list-0009"> <li> <p>low, high or unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD000493-sec-0044"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) </h5> <p>We describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We state whether attrition and exclusions were reported. We also mention the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or could be supplied by the trial authors, we re‐included missing data in the analyses. </p> <p>We assessed methods as having:</p> <p> <ul id="CD000493-list-0010"> <li> <p>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); </p> </li> <li> <p>high risk of bias (e.g. numbers or reasons for missing data unbalanced across groups; ‘as treated' analysis done with substantial departure of intervention received from that assigned at randomisation); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD000493-sec-0045"> <h5 class="title">(5) Selective reporting bias</h5> <p>We describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found. </p> <p>We assessed the methods as having:</p> <p> <ul id="CD000493-list-0011"> <li> <p>low risk of bias (where it is clear that all of the study’s prespecified outcomes and all expected outcomes of interest to the review have been reported); </p> </li> <li> <p>high risk of bias (where not all the study’s prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; the study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk of bias.</p> </li> </ul> </p> </section> <section id="CD000493-sec-0046"> <h5 class="title">(6) Other sources of bias</h5> <p>We describe for each included study any important concerns we had about other possible sources of bias. </p> <p>We assessed whether each study was free of other problems that could put it at risk of bias, as having: </p> <p> <ul id="CD000493-list-0012"> <li> <p>low risk of other bias;</p> </li> <li> <p>high risk of other bias;</p> </li> <li> <p>unclear risk of other bias.</p> </li> </ul> </p> </section> <section id="CD000493-sec-0047"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook</i> (<a href="./references#CD000493-bbs2-0067" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether they were likely to impact on the findings. We explored the impact of the level of bias through undertaking sensitivity analyses ‐ <i>see</i><a href="#CD000493-sec-0058">Sensitivity analysis</a>. </p> </section> </section> <section id="CD000493-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <section id="CD000493-sec-0049"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we present results as a summary risk ratio (RR) with a 95% confidence interval (CI).  </p> </section> <section id="CD000493-sec-0050"> <h5 class="title">Continuous data</h5> <p>For continuous data, we have used the mean difference (MD) if outcomes were measured in the same way between trials. In future updates, as appropriate, we plan to use the standardised mean difference (SMD) to combine trials that measure the same outcome, but use different methods.   </p> </section> </section> <section id="CD000493-sec-0051"> <h4 class="title">Unit of analysis issues</h4> <section id="CD000493-sec-0052"> <h5 class="title">Cluster‐randomised trials</h5> <p>We found no cluster‐randomised trials for this review, although if  cluster‐randomised trials had been available, we would have included them. In future updates, if identified and eligible, we will include cluster‐randomised trials in the analyses along with individually‐randomised trials. We will adjust either their sample sizes or standard errors using the methods described in the <i>Handbook</i> <i>[Section 16.3.4 or 16.3.6]</i> using an estimate of the intra cluster correlation co‐efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster‐randomised trials and individually‐randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomisation unit is considered to be unlikely. </p> <p>We will also acknowledge heterogeneity in the randomisation unit and perform a sensitivity analysis to investigate the effects of the randomisation unit. </p> </section> </section> <section id="CD000493-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>For included studies we noted levels of attrition. We explored the impact of included studies with high levels of missing data in the overall assessment of treatment effect by sensitivity analysis. </p> <p>For all outcomes, we analysed the data as far as possible on an intention‐to‐treat (ITT) basis, i.e. we made an attempt to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD000493-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity in each meta‐analysis using the Tau<sup>2</sup>, I<sup>2</sup> and Chi<sup>2</sup> statistics. We regarded heterogeneity as substantial if the Tau<sup>2</sup> is greater than zero and either I<sup>2</sup> is greater than 30% or there is a low P value (less than 0.10) in the Chi<sup>2</sup> test for heterogeneity. </p> </section> <section id="CD000493-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>There were insufficient studies (i.e. less than 10) to investigate reporting biases with funnel plots. </p> </section> <section id="CD000493-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 software (RevMan; <a href="./references#CD000493-bbs2-0102" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We used fixed‐effect meta‐analysis for combining data where it was reasonable to assume that studies were estimating the same underlying treatment effect, i.e. where trials were examining the same intervention, and we judged the trials’ populations and methods to be sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we detected substantial statistical heterogeneity, we used random‐effects meta‐analysis to produce an overall summary, if we considered an average treatment effect across trials was clinically meaningful. We treated the random‐effects summary as the average of the range of possible treatment effects and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. </p> <p>Where we have used random‐effects analyses, we present the results as the average treatment effect with its 95% confidence interval, and the estimates of  Tau<sup>2</sup> and I<sup>2</sup>. </p> </section> <section id="CD000493-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We carried out the following subgroup analyses.</p> <p> <ul id="CD000493-list-0013"> <li> <p>Total serum bile acid concentrations equal to or greater than 40 µmol/L versus total serum bile acid concentrations less than 40 µmol/L. </p> </li> </ul> </p> <p>We used primary outcomes only for the subgroup analysis. In this update we also report a subgroup analysis of one of the secondary outcomes (spontaneous preterm birth) as this was reported by one of the trials (<a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>). </p> <p>We assessed subgroup differences by interaction tests available within RevMan (<a href="./references#CD000493-bbs2-0102" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We report the results of subgroup analyses quoting the Chi<sup>2</sup> statistic and P value, and the interaction test I<sup>2</sup> value. </p> </section> <section id="CD000493-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>When appropriate, in future updates we will carry out sensitivity analyses to explore the effect of trial quality based on concealment of allocation, by excluding studies with unclear or high risk of bias for allocation concealment. </p> </section> <section id="CD000493-sec-0059"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>For this update we have assessed the certainty of the evidence using the GRADE approach, as outlined in the <a href="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html" target="_blank">GRADE handbook</a>, in order to assess the certainty of the body of evidence relating to the following outcomes for the main comparison (UDCA versus placebo): </p> <section id="CD000493-sec-0060"> <h5 class="title">Maternal</h5> <p> <ul id="CD000493-list-0014"> <li> <p>Pruritus (scores, change in score, improvement)</p> </li> </ul> </p> </section> <section id="CD000493-sec-0061"> <h5 class="title">Fetal/neonatal</h5> <p> <ul id="CD000493-list-0015"> <li> <p>Stillbirths or neonatal deaths</p> </li> <li> <p>Fetal distress/asphyxial events</p> </li> </ul> </p> <p><a href="http://www.guidelinedevelopment.org/" target="_blank">GRADEpro</a> Guideline Development Tool has been used to import data from Review Manager 5 (<a href="./references#CD000493-bbs2-0102" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>) in order to create ’Summary of findings’ tables. We have produced a summary of the intervention effect and a measure of certainty for each of the above outcomes using the GRADE approach. This addresses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence for each outcome. The evidence can be downgraded from 'high certainty' by one level for serious (or by two levels for very serious) limitations, depending on assessments as per the criteria above. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000493-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000493-sec-0062"></div> <section id="CD000493-sec-0063"> <h3 class="title">Description of studies</h3> <p><i>See</i><a href="./references#CD000493-sec-0312" title="">Characteristics of included studies</a>; <a href="./references#CD000493-sec-0313" title="">Characteristics of excluded studies</a>; <a href="./references#CD000493-sec-0315" title="">Characteristics of ongoing studies</a>. </p> <section id="CD000493-sec-0064"> <h4 class="title">Results of the search</h4> <p>See: <a href="#CD000493-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD000493-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD000493-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>For this update, we retrieved 17 new trial reports to assess. We also reassessed <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a> and <a href="./references#CD000493-bbs2-0032" title="MazzellaG , AzzaroliF . Intrahepatic cholestasis of pregnancy: clinical impact of ursodeoxycholic acid treatment. clinicaltrials.gov/ct2/show/NCT01226823 (first received 22 October 2010). ">Mazzella 2010</a> that were awaiting classification and ongoing in the previous version of the review. We included five new trials (nine reports) and excluded five. Three trials are awaiting further classification and two are ongoing. </p> </section> <section id="CD000493-sec-0065"> <h4 class="title">Included studies</h4> <p>The original review (2001) included nine randomised controlled trials (<a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>). The 2013 update included 11 new studies (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>; <a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>). In addition, one study (<a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>) was a conference abstract and excluded from the original review (<a href="./references#CD000493-bbs2-0128" title="BurrowsRF , ClavisiO , BurrowsE . Interventions for treating cholestasis in pregnancy. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD000493. [DOI: 10.1002/14651858.CD000493]">Burrows 2001</a>). This was included in the update. </p> <p>The updated search identified six new studies, five of which we judged to be eligible for inclusion (<a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>). </p> <p>Thus we now include 26 trials involving 2007 women in this review. See table of <a href="./references#CD000493-sec-0312" title="">Characteristics of included studies</a> for a full description. </p> <section id="CD000493-sec-0066"> <h5 class="title">Participants</h5> <p>All women had a diagnosis of intrahepatic cholestasis of pregnancy, based on the presence of pruritus in pregnancy and abnormalities of liver function. The onset of pruritus varied among the studies, occurring before week 19 (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>), after week 20 (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>), after week 28 (<a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>), after week 29 (<a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>), after week 32 (<a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>), after week 33 (<a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>), after week 35 (<a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>), in the second half of pregnancy (<a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>), the last trimester (<a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>) or the second or third trimester (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>). In one study (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>), women were randomised after week 24, irrespective of the time of onset of gestational pruritus. Eleven studies did not specify a time for onset of pruritus (<a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>). Generally, the inclusion criteria stipulated the severity and duration of pruritus, increased serum concentrations of bile acids/salts and/or other liver function assays, and consent to remain in hospital until the birth or to undergo extensive fetal monitoring, while the exclusion criteria stipulated absence of skin disease, chronic liver disease or other abnormalities unrelated to pregnancy. <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a> reported that one woman was in the study twice, during successive pregnancies. </p> </section> <section id="CD000493-sec-0067"> <h5 class="title">Interventions</h5> <p>Nine different pharmacological interventions were compared with placebo, with no treatment or with another intervention. However combination treatments were also evaluated, so we ended up with 14 comparisons (with some trials appearing in more than one comparison): </p> <p> <ul id="CD000493-list-0016"> <li> <p>UDCA versus placebo or no treatment ‐ 10 studies (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>); </p> </li> <li> <p>SAMe versus placebo ‐ four studies (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>); </p> </li> <li> <p>Guar gum versus placebo ‐ one study (<a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>); </p> </li> <li> <p>Activated charcoal versus no treatment ‐ one study (<a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>); </p> </li> <li> <p>Dexamethasone versus placebo ‐ one study (<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>); </p> </li> <li> <p>UDCA versus SAMe ‐ six studies (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>); </p> </li> <li> <p>UDCA versus dexamethasone ‐ one study (<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>); </p> </li> <li> <p>UDCA versus cholestyramine ‐ one study (<a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>); </p> </li> <li> <p>UDCA+SAMe versus placebo ‐ one study (<a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>); </p> </li> <li> <p>UDCA+SAMe versus SAMe ‐ four studies (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>); </p> </li> <li> <p>UDCA+SAMe versus UDCA ‐ six studies (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>); </p> </li> <li> <p>UDCA+Salvia versus UDCA ‐ one study (<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>); </p> </li> <li> <p>Yinchenghao decoction (YCHD) versus SAMe ‐ one study (<a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>); </p> </li> <li> <p>Danxioling Pill (DXLP) versus Yiganling ‐ one study (<a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>). </p> </li> </ul> </p> <p>There were no studies identified which examined the use of topical emollients.</p> <section id="CD000493-sec-0068"> <h6 class="title">Ursodeoxycholic acid (UDCA) versus placebo</h6> <p>(<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>) </p> <p>Participants in <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a> received UDCA 450 mg/day in two doses for 14 days.<br/>The treatment and control interventions were identical in two studies (<a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a> and relevant arms of <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>): 600 mg/day UDCA, or placebo (vitamin) given in two oral doses for 20 days (given after 30 weeks' gestation in <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>).<br/>Participants in <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> and <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a> received a higher dose of UDCA or placebo over a longer period of time. UDCA 1000 mg/day or placebo was given as a single daily dose for three weeks in <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> and as three divided doses or placebo (starch) in <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>.<br/>In <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>, women received UDCA (18 mg/kg body weight) three times a day for two weeks. The control group received a combination of 10% glucose, vitamin C and Inosine for two weeks. It is unclear whether the interventions were administered orally or by a parenteral route.<br/>Participants in <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> received UDCA 1000 mg daily increased in increments of 500 mg daily every three to 14 days up to a maximum UDCA dose 2000 mg/day if no biochemical or clinical improvement was observed.<br/>Participants in <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a> received UDCA 1000 mg daily or a placebo increased in increments of 500 mg daily every three to 14 days up to a maximum of 2000 mg daily if no biochemical or clinical improvement was observed.<br/>Participants in <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a> received UDCA 450 mg daily or a placebo for 14 days.<br/>Participants in <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a> received UDCA 1.5 g daily for seven days or nothing (i.e. an open‐label trial). </p> </section> <section id="CD000493-sec-0069"> <h6 class="title">S‐adenosylmethionine (SAMe) versus placebo</h6> <p>(<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>) </p> <p>In these studies, SAMe 800 mg dissolved in a 500 mL solution of saline (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>), 5% dextrose (<a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>) or 5% glucose (<a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>) was administered as a daily dose intravenously (IV) over the course of three (<a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>) or four hours (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>). The duration of administration was not reported in two studies (<a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>).<br/>A lower dose of SAMe 200 mg/day was also compared with placebo (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>). The intervention was administered up to the day of delivery (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>) or for a maximum of 20 days (<a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>).<br/>Placebo treatment was either 5% dextrose solution (<a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>), mannitol (800 mg) in a 5% glucose solution (<a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>), saline solution (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>) or a vitamin solution (<a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>). </p> </section> <section id="CD000493-sec-0070"> <h6 class="title">Guar gum versus placebo</h6> <p>(<a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>) </p> <p>Guar gum or placebo (wheat flour) at doses from 5 to 15 g/day (increases in dosage occurring at three‐day intervals) were given in three intermittent doses up until delivery. For the participants to be included in the intervention analysis, they had to take guar gum or placebo for at least 10 days. </p> </section> <section id="CD000493-sec-0071"> <h6 class="title">Activated charcoal versus no treatment</h6> <p>(<a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>) </p> <p>Activated charcoal as a water suspension was given in a dose of 50 g three times a day for eight days. </p> </section> <section id="CD000493-sec-0072"> <h6 class="title">Dexamethasone versus placebo</h6> <p>(<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>) </p> <p>Dexamethasone 12 mg/day was administered as a single daily oral dose for a week, followed by placebo for two weeks. Women in the control group took a single dose of placebo every day for three weeks. </p> </section> <section id="CD000493-sec-0073"> <h6 class="title">Ursodeoxycholic acid (UDCA) versus S‐adenosylmethionine (SAMe)</h6> <p>(<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>) </p> <p>These studies differed by dose, administration and duration of intervention.<br/><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> used the highest dose of UDCA (750 mg/day) and this was administered orally three times a day until birth.<br/>In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> and <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>, 600 mg/day of UDCA was administered as two oral daily doses for 20 days or until delivery respectively.<br/>In <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>, UDCA was given as a single oral dose of 450 mg/day until delivery. </p> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>, and <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a> administered 1000 mg/day of SAMe but the routes of administration and duration of intervention were different. In <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, SAMe 500 mg was administered IV twice daily for 12 days and subsequently as 500 mg twice daily oral dose until delivery. In <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>, SAMe was administered as a single intramuscular (IM) injection daily until birth. In <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>, it was given in two doses by oral route until delivery.<br/>In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, 800 mg/day of SAMe was administered daily in two doses as IV infusions. These were given for a maximum of 20 days. </p> <p>In <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> UDCA (250 mg given orally four times a day) was compared with SAMe (1000 mg IV four times daily) alone.<br/>In <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> UDCA (250 mg given orally four times a day) was compared with SAMe (1 g IV daily). </p> </section> <section id="CD000493-sec-0074"> <h6 class="title">Ursodeoxycholic acid (UDCA) versus dexamethasone</h6> <p>(<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>) </p> <p>UDCA 1000 mg was administered as a daily single daily oral dose for three weeks. This was compared with dexamethasone 12 mg/day given as a single oral dose for one week and placebo during weeks two and three. </p> </section> <section id="CD000493-sec-0075"> <h6 class="title">Ursodeoxycholic acid (UDCA) versus cholestyramine</h6> <p>(<a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>) </p> <p>UDCA (8 to 10 mg/kg body weight a day) was compared with cholestyramine (8 g/day). Both treatments were administered orally for two weeks. </p> </section> <section id="CD000493-sec-0076"> <h6 class="title">Yinchenghao decoction (YCHD) versus S‐adenosylmethionine (SAMe)</h6> <p>(<a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>) </p> <p>YCHD given twice daily orally for three weeks was compared with SAMe IV infusion of 2 x 500 mg daily for three weeks. </p> </section> <section id="CD000493-sec-0077"> <h6 class="title">Ursodeoxycholic acid and S‐adenosylmethionine (UDCA+SAMe) versus placebo</h6> <p>(<a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>) </p> <p>UDCA (600 mg/day, in two oral doses) plus SAMe (in the stable form of sulphate‐P‐toluenesulphonate diluted in 500 mL 5% dextrose and divided into two IV infusions (800 mg/day)) were compared with placebo (vitamin) administered for a maximum of 20 days. </p> </section> <section id="CD000493-sec-0078"> <h6 class="title">Ursodeoxycholic acid and S‐adenosylmethionine (UDCA+SAMe) versus S‐adenosylmethionine (SAMe) </h6> <p>(<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>) </p> <p>In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, UDCA (600 mg/day, in two oral doses) plus SAMe ( in the stable form of sulphate‐P‐toluenesulphonate diluted in 500 mL 5% dextrose and divided into two IV infusions (800 mg/day)) were compared with SAMe (as sulphate‐P‐toluenesulphonate diluted in 500 mL 5% dextrose and divided into two IV infusions (800 mg/day) administered for a maximum of 20 days.<br/>In <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, UDCA (3 x 250 mg/day oral doses until delivery) plus SAMe (2 x 500 mg/day given by slow infusion for 14 days) was compared with SAMe (2 x 500 mg/day given by slow infusion for 14 days) alone.<br/>In <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>, UDCA plus SAMe (dose not stated) was compared with SAMe (1000 mg IV four times daily) alone.<br/>In <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> UDCA (250 mg given orally four times a day) plus SAMe (1 g IV daily) was compared with SAMe (1 g IV daily). </p> </section> <section id="CD000493-sec-0079"> <h6 class="title">Ursodeoxycholic acid and S‐adenosylmethionine (UDCA+SAMe) versus ursodeoxycholic acid (UDCA) </h6> <p>(<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>) </p> <p>In <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, UDCA (3 x 250 mg/day oral doses until delivery) plus SAMe (2 x 500 mg/day given by slow infusion for 14 days) was compared with UDCA (3 x 250 mg/day oral doses until delivery) alone.<br/>In <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>, UDCA plus SAMe (dose not stated) was compared with UDCA (250 mg given orally four times daily) alone.<br/>In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, UDCA (600 mg/day, in two oral doses) plus SAMe (800 mg sulphate‐P‐toluenesulphatonate diluted in 500 mL 5% dextrose, in two IV infusions) was compared with UDCA (600 mg/day, in two oral doses) alone administered for a maximum of 20 days.<br/>In <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>, SAMe (Transmetil 1 g added to 250 mL 5% glucose administered as an IV infusion once daily) plus UDCA (250 mg oral pill twice daily) were compared with UDCA pill alone (250 mg oral pill twice daily) for 10 days<b>.</b> Participants in both groups received dexamethasone (10 mg once a day orally) for three days before starting the study drugs.<br/>In <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> UDCA (250 mg twice a day orally) combined with SAMe (1 g daily IV) was compared with UDCA (250 mg twice a day orally).<br/>In <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> UDCA (250 mg given orally four times a day) plus SAMe (1 g IV daily) was compared with UDCA (250 mg given orally four times a day). </p> </section> <section id="CD000493-sec-0080"> <h6 class="title">Ursodeoxycholic acid (UDCA)+Salvia versus ursodeoxycholic acid (UDCA)</h6> <p>(<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>) </p> <p>Salvia (10 mL in 10% 500 mL dextrose IV injection) and ursodeoxycholic acid (15 mg/kg/day divided into three oral doses a day) was compared with UDCA (same dose as above) only. Both were used for 14 days. </p> </section> <section id="CD000493-sec-0081"> <h6 class="title">Danxioling pill (DXLP) versus Yiganling</h6> <p>(<a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>) </p> <p>DXLP 9 g/day given three times a day orally for seven days was compared with Yiganling tablets given as four tablets three times a day for seven days. </p> </section> </section> <section id="CD000493-sec-0082"> <h5 class="title">Outcomes</h5> <p>The main outcomes in all studies included maternal, perinatal, and neonatal morbidity and mortality outcomes. </p> </section> <section id="CD000493-sec-0083"> <h5 class="title">Study dates, funding and conflicts of interest</h5> <p>For <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a> the dates the study was conducted, the funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> was conducted between January 1999 and March 2004. The study was funded by IGA MZ CR (No. NH/7376‐3). No conflicts of interest were reported. </p> <p><a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> was conducted between October 2008 and April 2010. The study was funded by the National Institute for Health Research (NIHR). LCC is funded by a Department of Health‐NHS clinical senior lecturer award, VG was funded by Nottingham University Hospitals NHS Trust and NIHR research for patient benefit programme, PTS is funded by Tommy’s Charity, and CW is funded by the Biomedical Research Centre at Imperial College Healthcare NHS Trust; JC is the founder of Obstetric Cholestasis Support UK, a support group for women and families affected by obstetric cholestasis; no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years; and no other relationships or activities that could appear to have influenced the submitted work. </p> <p><a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a> was conducted between 23 December 2015, and 07 August 2018. The study was funded by the National Institute for Health Research Efficacy and Mechanism Evaluation Programme. The authors declared the following conflicts of interest: LCC, JLB, EJ, RH, and JD report grants from the National Institute for Health Research (NIHR), during the conduct of the study. JD also reports grants from NIHR and Nutrinia, outside the submitted work. JGT is a co‐author of the Cochrane Review of treatment for obstetric cholestasis and a co‐author of a previous trial of UDCA to treat ICP. </p> <p>For <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a> the dates the study was conducted and conflicts of interest were not reported. The study was partially supported by a Ministerial grant (MURST 60%). </p> <p><a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a> was conducted between 1979 and 1982. The funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> was conducted between February 1999 and January 2002. The study was funded by FoU, Västra Götaland. The following conflicts of interest were reported: Dr Falk Pharma, manufacturers of UDCA supplied UDCA and placebos. </p> <p><a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a> was conducted in a three‐week period, although the dates are not reported, and the funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a> was conducted in a two‐year period, although the dates are not reported, and the funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a> was conducted between October 1999 and September 2002. The funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a> was conducted between June 2001 and July 2003. The funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> was conducted between March 1995 and July 1996. The funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a> was conducted between July 1993 and June 1995. The study was funded by FONDECYT, Chile, Grants no. 191‐1107 and 194‐0420. Conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> was conducted in a two‐year period, although the dates are not reported. The funding source was a Universidad de Chile (grant M‐15001) and FONDECYT (grant 0467/88). Conflicts of interest were not reported. </p> <p>For <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a> the dates the study was conducted were not reported. The study was funded by the Finnish Heart Foundation, Finnish Academy of Medical Sciences, the Paulo Foundation, the Juho Vainio Foundation and the Helsinki University Hospital. Conflicts of interest were that guar gum was received from Orion Company, Helsinki, Finland. </p> <p><a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a> was conducted between June 1996 and December 2001. The funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> was conducted between January 2012 and February 2014. The funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> was conducted between July 2009 and March 2011. The funding source and conflicts of interest were not reported. </p> <p><a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> was conducted between January 2012 and February 2014. The funding source and conflicts of interest were not reported. </p> </section> </section> <section id="CD000493-sec-0084"> <h4 class="title">Excluded studies</h4> <p>Seven studies were excluded. We excluded one study because we were unable to locate it (<a href="./references#CD000493-bbs2-0027" title="EliasE . A double blind, randomized placebo controlled trial (DBRCT) or ursodeoxycholic acid in obstetric cholestasis (OC). National Research Register (www.controlled-trials.com) (accessed 21 November 2001). ">Elias 2001</a>). Two studies were excluded because the intervention was not a pharmacological intervention (<a href="./references#CD000493-bbs2-0028" title="GautamS , GautamG . Laproscopy cholecystectomy in pregnant patients. Journal of Gastroenterology and Hepatology2013;28(Suppl 3):775. ">Gautam 2013</a>; <a href="./references#CD000493-bbs2-0029" title="JainR , SuriV , ChopraS , ChawlaYK , KohliKK . Obstetric cholestasis: outcome with active management. Journal of Obstetrics and Gynaecology Research2013;39(5):953-9. ">Jain 2013</a>). Two studies were excluded because no data were available (<a href="./references#CD000493-bbs2-0030" title="KohariK , NCT01965054. The use of fish oil supplementation in treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01965054 (first received 18 October 2013). ">Kohari 2013</a>; <a href="./references#CD000493-bbs2-0031" title="LiuSY , TanZY . Danyu mixture for pregnancy intrahepatic cholestasis. Shanghai Journal of Traditional Chinese Medicine1990;36(7):9-10. ">Liu 1990</a>). One study previously an ongoing study was excluded because it was withdrawn from the trial registry in 2016 (<a href="./references#CD000493-bbs2-0032" title="MazzellaG , AzzaroliF . Intrahepatic cholestasis of pregnancy: clinical impact of ursodeoxycholic acid treatment. clinicaltrials.gov/ct2/show/NCT01226823 (first received 22 October 2010). ">Mazzella 2010</a>). One study was excluded due to a particularly complex pharmacological intervention (<a href="./references#CD000493-bbs2-0033" title="ShiDY , ChenH , TianXY . Clinical and experimental study on wuling pill in treating gestation period intrahepatic cholestasis. Chinese Journal of Integrated Traditional and Western Medicine2006;26(2):114-8. ">Shi 2006</a>). For further details, <i>see</i><a href="./references#CD000493-sec-0313" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD000493-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risks of bias for the included studies is provided in the following figures: <a href="#CD000493-fig-0002">Figure 2</a>; <a href="#CD000493-fig-0003">Figure 3</a>; <a href="#CD000493-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD000493-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD000493-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <div class="figure" id="CD000493-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000493-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD000493-sec-0086"> <h4 class="title">Allocation</h4> <p>Apart from four studies (<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>) which were quasi‐randomised, all other studies were randomised controlled trials. Seven trials reported adequate methods for sequence generation (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>). Three studies (<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>) used alternation by hospital admission in order to generate a random sequence. In <a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>, participants were divided into two groups based on the date of hospital admission. <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a> and <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a> mentioned that the study participants were 'randomly assigned' to the two interventions, but it is unclear how this random sequence was generated. In <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>, participants were randomised according to a pre‐established code, but it is unclear how this code was derived. It is unclear whether the remaining studies had used a random sequence for intervention allocation. </p> <p>Allocation concealment was adequate for three trials (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>). <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a> and <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> used central allocation using a web‐based database. <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> used sequentially‐numbered drug containers of identical appearance. </p> <p>There was a high risk of possible selection bias in three trials (<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>) and this was unclear in the 19 remaining trials. </p> </section> <section id="CD000493-sec-0087"> <h4 class="title">Blinding</h4> <p>Blinding of participants or investigators or both was reported in eight studies. In <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a> participants, clinical care providers, outcome assessors and data analysts were all masked to allocation and it clearly describes how this was achieved. Identical UDCA tablets and placebo tablets were produced and shipped to site pharmacies. Packs were labelled with unique identifiers according to a randomly‐generated sequence known only to the manufacturing unit and the trial programmers. A research team member entered baseline data on a web‐based database at study enrolment and then allocated a pack number using the web‐based randomisation programme, which corresponded to a pack for dispensing by that site’s pharmacy. </p> <p>In three studies participants and investigators were blinded to group allocation, but no details on blinding of outcome assessment are given (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>). For <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> investigator, pharmacist and participant were all blinded to group allocation and it was conducted in the same way as described for <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>. <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a> used identical UDCA and placebo capsules. <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> used identical‐looking UDCA, placebo and empty capsules. The empty capsules were filled with dexamethasone at the hospital pharmacy. </p> <p><a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> was unclear about how they blinded participants and investigators. </p> <p>In three of these studies, although blinding of both participants or investigators or both was reported (<a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>) it is unclear how this was performed. </p> <p>Two studies were single‐blinded, so that only the investigators were informed of which treatment participants were receiving (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>) and we therefore judged them to be at high risk. <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a> made no mention of a placebo, and we interpreted this to mean it was an open‐label trial and have therefore judged it to be at high risk. </p> <p>In nine studies no blinding occurred, as the interventions were administered by different routes and it was therefore not possible to blind, so we have judged them to be high risk (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>). In the four remaining studies it is unclear whether the participants or investigators or both were blinded to trial allocation (<a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>).  </p> <p>Blinding of outcome assessors was reported in one study (<a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>).  </p> <p>Blinding of outcome assessors was not reported in 24 studies and we therefore judged them to be at unclear risk of bias (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>). </p> </section> <section id="CD000493-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>Twelve of the 26 studies had a low risk of attrition bias as there were no losses to follow‐up (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>). </p> <p>In <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>, outcomes were reported for 25 participants (86%) for serum alanine transaminase (ALT) and aspartate transaminase (AST), for 27 participants (93%) for alkaline phosphatase (ALP), for 21 participants (72%) for serum bilirubin concentrations out of 29 participants receiving Danxioling, and for 16 of 29 participants (55%) for serum bilirubin concentrations in the Yiganling group. </p> <p>Five of the 26 studies had a high risk of attrition bias as the losses to follow‐up were unreported (<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>). Outcomes were reported in 15 of 25 participants randomised (63%) in <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>. <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a> excluded from the analysis nine women who delivered before completion of two weeks of treatment. </p> <p>Nine of the 26 studies had an unclear risk of attrition bias due to a lack of information about losses to follow‐up (<a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>). Outcomes were reported for 39 of 48 participants randomised (81%) in <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>, and for 18 of 20 (90%) in <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>. The number of participants analysed in the results was unclear in <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>. <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> reported 20 cases to have been eliminated and not included in the analysis. However, It was unclear how many of these from each randomised group were lost to follow‐up (<a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>), as only the total number of cases eliminated from the analysis was reported. </p> </section> <section id="CD000493-sec-0089"> <h4 class="title">Selective reporting</h4> <p>Three of the 26 studies had a low risk of selective reporting (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>), as all the prespecified outcomes were reported. Ten of the 26 studies had an unclear risk of selective reporting (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>) as the trials were unregistered. Thirteen of the 26 studies had a high risk of selective reporting (<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>), as either one or more outcomes of interest were reported incompletely or there was a failure to report key outcomes such as perinatal mortality. </p> <p>While most trials reported maternal pruritus after treatment, variable and incomplete reporting (together with variance in measurement parameter reported) precluded pooling of data for this outcome. </p> <p>The other primary outcomes of perinatal mortality and fetal distress were not reported in any of the trials. In addition, several trials reported some outcomes only in graphical form. </p> </section> <section id="CD000493-sec-0090"> <h4 class="title">Other potential sources of bias</h4> <p>Eleven of the 26 studies had a low risk of additional sources of bias (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>; <a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>; <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>) where no other additional sources of bias were identified by the authors. </p> <p>Six of the 26 studies had an unclear risk of additional sources of bias (<a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>), due to a lack of information. </p> <p>Nine of the 26 studies had a high risk of other potential sources of bias (<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>). In <a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a> it is unclear why there are 72 women in the experimental group and 58 women in the control group, with insufficient detail given on randomisation to be sure that this imbalance is a result of randomisation. In <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a> there was some concern about the analyses chosen and reported. In <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> the planned sample size reported in the paper was 240 (80 per group). No explanation was given for stopping after 130 participants had been recruited. In <a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a> there was an imbalance in the numbers of women randomised to each group. In <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a> the sample size was data‐driven, and in <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> we have concerns about the absence of any missing data. In <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a> there was some concern about the analyses chosen and reported. In <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a> no justification was given for the sample size of 20 women and there was inconsistent reporting of the recruitment duration. </p> </section> </section> <section id="CD000493-sec-0091"> <h3 class="title" id="CD000493-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD000493-tbl-0001"><b>Summary of findings 1</b> Ursodeoxycholic acid (UDCA) versus placebo</a> </p> <section id="CD000493-sec-0092"> <h4 class="title">1. Ursodeoxycholic acid (UDCA) versus placebo</h4> <p>Nine trials (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>; <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>) involving 1037 women looked at this comparison. <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a> reported on UDCA versus no treatment. </p> <section id="CD000493-sec-0093"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0094"> <h6 class="title">Pruritus</h6> <p>All nine trials (1037 women) comparing UDCA and placebo reported this outcome. Four studies (830 women) used a 100 mm visual analogue scale (VAS), four studies (105 women) evaluated itching on a 0 ‐ 4 categorical scale, and one study (18 women) did not elaborate on the methods used to assess pruritus. Studies that used the 0 ‐ 4 scale (0 = absence of pruritus, 1 = occasional pruritus, 2 = discontinuous pruritus every day, with prevailing asymptomatic lapses, 3 = discontinuous pruritus with prevailing symptomatic lapses, and 4 = constant pruritus) analysed the data as a continuous outcome, which is not ideal as the assumption of normality on a short scale will not be met. We therefore planned to dichotomise the data by classifying a pruritus score of 0 ‐ 2 as mild pruritus, and 3 ‐ 4 as severe pruritus. We also planned to dichotomise pruritus outcomes after the end of the intervention as 'improvers' and 'non‐improvers'. Only <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a> allowed dichotomisation of data. We could not pool dichotomous results from any of these trials, due to the differing methods of measuring and reporting pruritus. </p> <p>We were only able to pool results from two studies (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>) out of three reporting a pruritus score using a 100 mm VAS. Pooled results from the two studies (715 women) reported a small reduction in pruritus score (out of 100) for UDCA compared with placebo: mean difference (MD) −7.64, 95% confidence interval (CI) −9.69 to −5.60; moderate‐certainty evidence; <a href="./references#CD000493-fig-0004" title="">Analysis 1.1</a>. It is worth noting that the 95% CI around the effect was only 9 mm, i.e. smaller than the minimum worthwhile treatment effect for most participants and doctors surveyed. </p> <p>Results that we were able to pool or present in forest plot or combine in meta‐analysis:</p> <p> <ul id="CD000493-list-0017"> <li> <p>In <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>, a weekly assessment of pruritus was performed in all the study participants by the same clinician using the 0 ‐ 4 scoring system. They reported a significant improvement in pruritus score after two weeks (P &lt; 0.01; 15 women) and three weeks (P = 0.02; 15 women) of treatment with UDCA compared with placebo. Data for improvement in pruritus score were presented in a forest plot as a graph, although they represent findings from a single study. Similar numbers of women (seven of the eight women in the UDCA group and five of the seven women in the placebo group) showed a reduction in pruritus score after three weeks (risk ratio (RR) 1.23, 95% CI 0.72 to 2.10; <a href="./references#CD000493-fig-0005" title="">Analysis 1.2</a>); all seven 'improvers' in the UDCA group had low scores (under 1.5) compared with two of the five 'improvers' in the placebo group. </p> </li> <li> <p><a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> prespecified in their trial protocol, published before data unblinding, that their primary outcome was to be the mean of all worst itching scores in the preceding 24 hours (100 mm VAS) measured between randomisation and delivery. The authors of this trial surveyed participants and obstetricians: each group considered that the mean minimum worthwhile improvement would be a 30 mm difference, reported within the main trial publication.bChappell 2012 reported the mean of average itching scores over the preceding 24 hours between randomisation and delivery, and showed a small reduction in pruritus (MD −18.60, 95% CI −27.52 to −9.68; (Analysis 1.3)), but the 95% CI around the effect was still less than 30 mm. </p> </li> </ul> </p> <p>We were unable to pool the results or present the data in forest plots for the following trials, and have therefore summarised the findings as reported by the studies: </p> <p> <ul id="CD000493-list-0018"> <li> <p>In <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>, pruritus was assessed before treatment (day 0) and at five‐day intervals thereafter, on a 0 ‐ 4 scale. Pruritus score was reported as mean and standard deviation (SD) at day 0 and day 20, favouring UDCA over placebo. </p> </li> <li> <p>In <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>, no difference in pruritus score (100 mm VAS) was seen between the UDCA and placebo groups after three weeks of treatment (94 women; no P value reported). However, in the 23 women with serum bile acids at least 40 μmol/L (subsequently defined as severe cholestasis), the pruritus score fell to a mean of about 15 in the UDCA group compared with a mean of about 52 in the placebo group. </p> </li> <li> <p>In <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a> (20 women), the pruritus score fell to a mean of 2.5 in the UDCA group compared with a mean of 7.5 in the placebo group. No SDs were reported in the paper. </p> </li> <li> <p><a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a> reported a significant improvement in pruritus scores within two weeks in the UDCA group. </p> </li> <li> <p>In <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>, pruritus was evaluated on a 0 ‐ 4 scale. Results were reported as mean and SD at trial entry and two weeks later. After 14 days of treatment, a reduction in the pruritus scores was observed in the UDCA group compared with the placebo group. </p> </li> <li> <p>In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, pruritus was evaluated by the participant every three days up to 24 hours after delivery using the 0 ‐ 4 scoring system. The change in pruritus score after 20 days of treatment was analysed as a continuous outcome and reported as mean and SD. A significant reduction in pruritus score was observed with both the UDCA and placebo groups. </p> </li> <li> <p>In <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>, itching was reported on a four‐point scale (0 = none, 1 = mild, 2 = moderate not requiring drug treatment, 3 severe requiring drug treatment). The timing was not reported. Treatment with UDCA appeared to have a large effect. Distribution was from 'no treatment' 14 women with moderate and eight women severe itch versus 'UDCA' in which four women had moderate itch and none severe itch. </p> </li> </ul> </p> </section> </section> <section id="CD000493-sec-0095"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0096"> <h6 class="title">Stillbirth</h6> <p>Six studies (955 women) reported stillbirth, with zero events in both groups for two studies (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0011" title="JoutsiniemiT , TimonenS , LeinoR , PaloP , EkbladU . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: a randomized controlled trial. Archives of Gynecology and Obstetrics2014;289(3):541-7. NCT01576458. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. clinicaltrials.gov/ct2/show/NCT01576458 (first received 12 April 2012). ">Joutsiniemi 2014</a>).  The evidence is very uncertain about the effect of UDCA on stillbirth because of limitations in study design and very few events reported: four out of the six studies reported seven stillbirths in total, (1/480 versus 6/475; average RR 0.33, 95% CI 0.08 to 1.37; random‐effects analysis; 955 women; very low‐certainty evidence; <a href="./references#CD000493-fig-0007" title="">Analysis 1.4</a>). </p> <p>In <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>, two women had "fetal death", classified by us as stillbirth, in the no‐treatment group. We rated the study as being at high risk of bias in most domains, with many expected data items missing, and a number of the other reported results deemed by us as implausible. </p> <p>In <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>, a woman on clomipramine for long‐term depressive disorder experienced itching from 33 weeks' gestation. After going into spontaneous labour at week 38, intrauterine death was diagnosed. Her serum bile acid concentrations were 16 µmol/L, both at trial inclusion and two weeks later. It is unclear from the information provided in the report whether the stillbirth could be attributable to intrahepatic cholestasis of pregnancy. </p> <p>In <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>, the woman with a stillbirth had received placebo for two weeks. The authors wrote: "Minor signs of fetal distress had been noticed a few hours before fetal death, but the decision to perform a caesarean section was wrongly delayed and fetal death occurred". </p> <p>In <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>, three women (of 605) had a stillbirth, i.e. in one woman taking UDCA and two women taking placebo. In the two women in the placebo group, one woman who had a peak bile acid of 80 µmol/L, and also had influenza A confirmed by throat swab at the time of stillbirth at 37 weeks. The other woman had a peak bile acid of 21 µmol/L and had a stillbirth at 35 weeks. </p> <p>No neonatal deaths were reported.</p> </section> <section id="CD000493-sec-0097"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>Six of the nine trials comparing UDCA with placebo reported fetal distress or asphyxial events or both in some form, although the evidence is very uncertain about the effect of UDCA because of limitations in study design and very little data reported (average RR 0.70, 95% CI 0.35 to 1.40; random‐effects analysis; Tau<sup>2</sup> = 0.25; I<sup>2</sup> = 34%; 6 trials, 944 women; very low‐certainty evidence; <a href="./references#CD000493-fig-0008" title="">Analysis 1.5</a>). </p> <p>In <a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a> and <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>, this outcome included women who had operative births for fetal distress, and in <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a> it was defined as abnormal results of antepartum testing prompting delivery. <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> defined asphyxial events as all operative births due to asphyxia, umbilical arterial pH less than 7.05 or Apgar score less than seven at five minutes. In <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a> one baby from the UDCA group and seven babies from the placebo group were reported to have asphyxia neonatorum (which was not clearly defined in the paper). <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> reported asphyxial events defined as induction or caesarean section for fetal compromise. </p> </section> <section id="CD000493-sec-0098"> <h6 class="title">Subgroup analysis (serum bile acid concentrations ≥ 40 µmol/L versus serum bile acid concentrations &lt; 40 µmol/L) </h6> <p><a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> presented data for the subgroups of serum bile acids equal to or greater than 40 µmol/L (RR 0.31, 95% CI 0.01 to 6.85; 23 women) versus serum bile acids less than 40 µmol/L (RR 1.03, 95% CI 0.15 to 6.90; 71 women) for one of this review's primary outcomes (asphyxial events). We acknowledge that there were too few data included in this analysis to identify any differences between subgroups (<a href="./references#CD000493-fig-0009" title="">Analysis 1.6</a>), (test for subgroup differences: Chi<sup>2</sup> = 0.42, df = 1 (P = 0.52), I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD000493-sec-0099"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0100"> <h6 class="title">Biochemical assessments</h6> <p>Two trials reported a reduction in serum bile acids after treatment with UDCA compared with placebo (MD −20.45, 95% CI −26.07 to −14.84; 2 trials, 519 women; <a href="./references#CD000493-fig-0010" title="">Analysis 1.7</a>). <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> (32 women) reports a reduction in serum bile acids after treatment with UDCA compared with placebo (MD −30.40, 95% CI −37.48 to −23.32; 16 women; <a href="./references#CD000493-fig-0010" title="">Analysis 1.7</a>). Although the I<sup>2</sup> score of 95% suggests a high level of heterogeneity between these trials, there is no obvious explanation for this in the two papers, nevertheless, in view of this, these results should be interpreted with caution. </p> <p><b>Serum alanine aminotransferase (ALT)</b> concentrations were lower after treatment with UDCA compared with placebo in four trials (581 women) (average MD −68.73 IU/L, 95% CI −104.09 to −33.38; random‐effects analysis; <a href="./references#CD000493-fig-0011" title="">Analysis 1.8</a>). <a href="./references#CD000493-fig-0012" title="">Analysis 1.9</a> is presented as change data. Although ALT changed in the same direction in both trials, the size of the change is much larger in <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, such that the I<sup>2</sup> score is 96%. Although there is no obvious explanation in the two papers, in view of this, these results should be interpreted with caution. </p> <p><a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> reported liver function tests only graphically, as medians and P values. The final serum bile acid concentrations were lower after treatment in the UDCA group compared with the placebo group (P = 0.001). There was a greater reduction in serum ALT in the UDCA group compared with the placebo group (P = 0.01). <a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a> reported a reduction in serum ALT and bile acid concentrations to the upper limit of normal pregnancy values in the UDCA group, but did not report numerical or graphical data by randomisation group. </p> </section> <section id="CD000493-sec-0101"> <h6 class="title">Caesarean section (and mode of birth)</h6> <p>Five trials found little to no differences between UDCA and placebo for rates of caesarean section (RR 1.05, 95% CI 0.89 to 1.23; 5 trials, 850 women; <a href="./references#CD000493-fig-0013" title="">Analysis 1.10</a>). <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> did not report caesarean births but did indicate that rates of elective birth (both caesarean and vaginal) were not very different between the two groups (32% for UDCA and 38% for placebo). </p> </section> <section id="CD000493-sec-0102"> <h6 class="title">Postpartum haemorrhage</h6> <p>There was little to no difference in the rates of postpartum haemorrhage in three trials reporting this outcome (RR 0.94, 95% CI 0.76 to 1.15; 731 women; <a href="./references#CD000493-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD000493-sec-0103"> <h6 class="title">Adverse effects of medication</h6> <p>Four trials reported on adverse effects of medication (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>). There was little to no difference between the two groups (RR 0.80, 95% CI 0.56 to 1.14; 4 trials, 824 women; <a href="./references#CD000493-fig-0015" title="">Analysis 1.12</a>). </p> <p>No adverse effects of medication for mothers or babies in either group were reported in four trials (<a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>;<a href="./references#CD000493-bbs2-0004" title="DiaferiaA , NicastriPL , TartagniM , LoizziP , IacovizziC , Di LeoA . Ursodeoxycholic acid therapy in pregnant women with cholestasis. International Journal of Gynecology and Obstetrics1996;52(2):133-40. ">Diaferia 1996</a>). </p> <p>In <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>, one participant in the UDCA group experienced diarrhoea and one in the placebo group suffered a severe headache. <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a> reported that one woman in the UDCA group experienced transient morning nausea and mild vomiting, which resolved after changing the time of UDCA intake. <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> reported 13 adverse events (seven mild, six moderate) in the treatment group and 10 in the placebo group (eight mild, two moderate). The drug was stopped due to adverse events of medication in one participant in the treatment group and one in the placebo group. </p> <p><a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a> reported 33 adverse events of medication (31 adverse events, two serious adverse events) in the treatment group and 48 (42 adverse events, six serious adverse events) in the placebo group. The drug was stopped due to adverse events of medication in one participant in the placebo group who experienced a serious adverse event. See <a href="./references#CD000493-fig-0015" title="">Analysis 1.12</a>. It seems odd that there were more adverse events in the placebo group; this must be a chance effect. </p> </section> </section> <section id="CD000493-sec-0104"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0105"> <h6 class="title">Meconium‐stained liquor</h6> <p>There may be a reduction in the observation of meconium‐stained liquor with UDCA compared with placebo groups according to four trials in the pooled analysis (average RR 0.63, 95% CI 0.39 to 1.00; random‐effects analysis: Tau<sup>2</sup> = 0.11; I<sup>2</sup> = 51%; 4 trials, 910 women; <a href="./references#CD000493-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD000493-sec-0106"> <h6 class="title">Mean gestational age at birth</h6> <p>In five trials there was a small increase in gestational age at birth in the UDCA group (average MD 1.50 weeks, 95% CI 0.20 to 2.80; random‐effects analysis: Tau<sup>2</sup> = 2.53; I<sup>2</sup> = 90%; 5 trials, 800 women; <a href="./references#CD000493-fig-0017" title="">Analysis 1.14</a>). However, given the high heterogeneity (I<sup>2</sup> = 90%) between the trials for this outcome, we tested the effect of removing the three smallest trials, leaving only the two Chappell trials. The heterogeneity remained at 69%, but the 95% CI for the mean difference (MD 0.36, 95% CI −0.30 to 1.03) included no effect on gestational age at birth (data not reported). </p> <p><a href="./references#CD000493-bbs2-0014" title="LeinoR , EkbladU , IrjalaK , ErkkolaR . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Prenatal and Neonatal Medicine1998;3 Suppl 1:67. ">Leino 1998</a> reported a higher birthweight in the UDCA group coinciding with advanced gestation at birth in this group, but did not report any numerical data in the comparison groups. </p> </section> <section id="CD000493-sec-0107"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>In three trials, little to no difference was seen in rates of spontaneous preterm birth at less than 37 weeks between the UDCA and placebo groups (RR 0.78, 95% CI 0.49 to 1.23; 3 trials, 749 women; <a href="./references#CD000493-fig-0018" title="">Analysis 1.15</a>). <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> reported that two women in the UDCA group had spontaneous preterm labour but did not report this outcome for the women in the placebo group. </p> </section> <section id="CD000493-sec-0108"> <h6 class="title">Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</h6> <p>Three trials (two different from the three reporting spontaneous preterm birth above) reported the total number of preterm births at less than 37 weeks of gestation. There were fewer total preterm births in the UDCA group compared with placebo (average RR 0.60, 95% CI 0.37 to 0.97; random‐effects analysis: Tau<sup>2</sup> = 0.10; I<sup>2</sup> = 55%; 3 trials, 819 women; <a href="./references#CD000493-fig-0019" title="">Analysis 1.16</a>). </p> <p>The I<sup>2</sup> is high at 55%, so we tested the effect of removing the smallest trial (<a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>), leaving <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> and <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>. When we did this the I<sup>2</sup> was 48% (RR 0.69, 95% CI 0.46 to 1.06). In view of this, although the result was still consistent with a reduction, the upper 95% CI was also compatible with a slight increase in total preterm births, and so we are less certain of the findings. </p> </section> <section id="CD000493-sec-0109"> <h6 class="title">Admission to neonatal unit</h6> <p>Two trials reported little to no difference in admission rates to the neonatal intensive care unit between the UDCA and the placebo groups (RR 0.77, 95% CI 0.55 to 1.08; 2 trials, 764 women; <a href="./references#CD000493-fig-0020" title="">Analysis 1.17</a>). </p> </section> </section> </section> <section id="CD000493-sec-0110"> <h4 class="title">2. S‐adenosylmethionine (SAMe) versus placebo</h4> <p>Four trials (<a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>; <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>) involving 82 women looked at this comparison. </p> <section id="CD000493-sec-0111"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0112"> <h6 class="title">Pruritus</h6> <p>Four trials (82 women) reported this outcome. <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a> (30 women) reported improvements in pruritus score with SAMe, whereas <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a> (18 women) reported reduction in pruritus with 800 g daily dose of SAMe but not with 200 g daily dose. Two studies (<a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a>) (34 women) reported an improvement in the pruritus score with both SAMe and placebo. None of these studies performed a subgroup analysis for improvement in pruritus in women with bile acids ≥ 40 µmol/L. </p> <p>Three studies (52 women) evaluated itching on a 0 ‐ 4 scale. Data were reported as mean and SD. We planned to dichotomise and re‐analyse the data but this was not possible because pruritus scores at trial entry and after intervention were not reported. </p> <p> <ul id="CD000493-list-0019"> <li> <p><a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a> assessed pruritus on day 0 (before entering the study), and at days 10 and 20 of treatment. Pruritus was graded from 0 to 4. The reductions in mean grade of pruritus score after 10 and 20 days of treatment were analysed and presented as a continuous outcome. A reduction in pruritus grade was reported with 800 g daily dose of SAMe (P &lt; 0.02 after day 10 and &lt; 0.01 after day 20), compared with placebo, but not for the 200 g daily dose. </p> </li> <li> <p><a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a> assessed pruritus on a 10 cm analogue scale every three days up to 24 hours after delivery. The authors reported the mean pruritus scores after treatment as lower (better) in the SAMe group compared with the placebo group (P &lt; 0.01; 30 women), but gave no numerical data. </p> </li> <li> <p><a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> evaluated pruritus on a 0 ‐ 4 scale every three days. The mean changes in pruritus score in the two groups were reported as a continuous outcome. A reduction in mean pruritus score was seen both in the SAMe group (P &lt; 0.01; 8 women) and in the placebo group (P &lt; 0.01; 8 women). </p> </li> <li> <p><a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> assessed the severity of pruritus on a 0 ‐ 4 scale immediately before treatment and every five days until delivery, one to three days after delivery and one to three months afterwards. The scores were analysed as a continuous outcome. The severity of pruritus was reduced in both groups, with the mean pruritus score decreasing more in the placebo group, but this difference was not large. </p> </li> </ul> </p> </section> </section> <section id="CD000493-sec-0113"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0114"> <h6 class="title">Stillbirth/neonatal death</h6> <p><a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> (18 participants) reported this outcome, with no stillbirths or neonatal deaths (<a href="./references#CD000493-fig-0021" title="">Analysis 2.1</a>). </p> </section> <section id="CD000493-sec-0115"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>In <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>, all the infants born to women in the SAMe group had Apgar scores of seven or above at five minutes. They did not report these figures for the placebo group, making comparisons impossible. </p> <p>All the newborns in <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> had Apgar scores of seven or above in both the groups. Caesarean sections were performed for various indications in this trial, including fetal distress, but the actual number of caesarean sections for this indication was not specified. </p> </section> </section> <section id="CD000493-sec-0116"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0117"> <h6 class="title">Biochemical assessments</h6> <p>In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> (16 women), reductions in serum bile acids, and serum ALT were greater in the SAMe group compared with placebo (<a href="./references#CD000493-fig-0022" title="">Analysis 2.2</a>; <a href="./references#CD000493-fig-0023" title="">Analysis 2.3</a>). In <a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a>, the final values of serum transaminases, conjugated bilirubin and total bile acids were reported to be lower in women treated with SAMe 800 mg a day than in women who received placebo (total of 12 women for this comparison). In <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a> (30 women), after a mean 18 days of treatment with SAMe, serum total bile acids, ALT and AST were all reported to be lower than in the placebo group (P = 0.01 for all three comparisons). <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> (18 women) reported no differences in results of the various liver function tests, but these were only presented in graphical form. </p> </section> <section id="CD000493-sec-0118"> <h6 class="title">Caesarean section</h6> <p>There were few to no differences in <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> between the SAMe and placebo groups for caesarean section (RR 1.14, 95% CI 0.75 to 1.74; 18 women; <a href="./references#CD000493-fig-0024" title="">Analysis 2.4</a>). </p> </section> <section id="CD000493-sec-0119"> <h6 class="title">Adverse effects</h6> <p><a href="./references#CD000493-bbs2-0007" title="FrezzaM , PozzatoG , ChiesaL , StramentinoliG , di PadovaC . Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine. Hepatology1984;4(2):274-8. ">Frezza 1984</a> reported that SAMe was well tolerated by women and that no adverse effects were seen, and <a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a> recorded no adverse effects for women or their children. <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> reported that one woman experienced problems in peripheral veins due to prolonged daily IV infusions. </p> </section> </section> <section id="CD000493-sec-0120"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0121"> <h6 class="title">Spontaneous labour/birth at less than 37 weeks</h6> <p><a href="./references#CD000493-bbs2-0008" title="FrezzaM , CammareriG , di PadovaC , Italian Study Group for ICP . Beneficial effects of S-adenosylmethionine in pregnant women with cholestasis: results of a multicenter controlled trial (abstract). Journal of Hepatology1987;5(Suppl 1):S27. FrezzaM , CentiniG , CammareriG , Le GrazieC , Di PadovaC . S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepato-Gastroenterology1990;37(Suppl 2):122-5. ">Frezza 1990</a> reported that two women in the SAMe group and five in the placebo group had preterm labour before 37 weeks (RR 0.40, 95% CI 0.09 to 1.75; 30 women; <a href="./references#CD000493-fig-0025" title="">Analysis 2.5</a>). <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> reported three preterm births in the SAMe group but did not state how many there were in the placebo group. <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> reported the total preterm births (see below) but did not specify the number of spontaneous preterm births. </p> </section> <section id="CD000493-sec-0122"> <h6 class="title">Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</h6> <p>Six women in the SAMe group in <a href="./references#CD000493-bbs2-0019" title="RibaltaJ , ReyesH , GonzalezMC , IglesiasJ , ArreseM , PoniachikJ , et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology1991;13(6):1084-9. ">Ribalta 1991</a> versus eight in the placebo group had preterm births (RR 0.75, 95% CI 0.45 to 1.26; 18 women; <a href="./references#CD000493-fig-0026" title="">Analysis 2.6</a>). </p> <p>The following secondary outcomes were not reported for this comparison: postpartum haemorrhage, meconium‐stained liquor, mean gestational age at birth, or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0123"> <h4 class="title">3. Guar gum versus placebo</h4> <p>One trial (<a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a>) involving 39 women studied this comparison. </p> <section id="CD000493-sec-0124"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0125"> <h6 class="title">Pruritus</h6> <p>In <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a> both investigators and participants assessed change in pruritus following treatment. From the women's perspective, nine (48%) women receiving guar gum and five (25%) receiving placebo experienced a reduction in pruritus (RR 1.89, 95% CI 0.77 to 4.64; <a href="./references#CD000493-fig-0027" title="">Analysis 3.1</a>). From the investigator's perspective, six (32%) women receiving guar gum and five (25%) receiving placebo had a reduction in pruritus (RR 1.26, 95% CI 0.46 to 3.46; <a href="./references#CD000493-fig-0027" title="">Analysis 3.1</a>). There were few to no differences between groups. </p> </section> </section> <section id="CD000493-sec-0126"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0127"> <h6 class="title">Stillbirth/neonatal death</h6> <p>No neonatal or infant deaths were reported.</p> </section> <section id="CD000493-sec-0128"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>This outcome was not reported.</p> </section> </section> <section id="CD000493-sec-0129"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0130"> <h6 class="title">Biochemical assessments</h6> <p>There were few to no differences seen in <a href="./references#CD000493-bbs2-0020" title="GyllingH , RiikonenS , NikkilaK , SavoniusH , MiettinenTA . Oral guar gum treatment of intrahepatic cholestasis and pruritus in pregnant women: effects on serum cholesterol and other non-cholesterol sterols. European Journal of Clinical Investigation1998;28(5):359-63. RiikonenS , SavoniusH , GyllingH , NikkilaK , TuomiAM , MiettinenTA . Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavia2000;79(4):260-4. ">Riikonen 2000</a> between guar gum and placebo in reducing the concentrations of serum bile acids (µmol/L) (MD −7.40, 95% CI −24.22 to 9.42; 39 women; <a href="./references#CD000493-fig-0028" title="">Analysis 3.2</a>) and serum ALT (U/L) (MD −37.50, 95% CI −137.33 to 62.33; 39 women; <a href="./references#CD000493-fig-0029" title="">Analysis 3.3</a>). </p> </section> <section id="CD000493-sec-0131"> <h6 class="title">Adverse effects of medication</h6> <p>Eight women (42%) in the guar gum group and six (30%) in the placebo group reported mild abdominal distress, diarrhoea and flatulence during the first days of treatment, showing little to no difference overall (RR 1.40, 95% CI 0.60 to 3.29; <a href="./references#CD000493-fig-0030" title="">Analysis 3.4</a>). None of the participants discontinued the study. </p> </section> </section> <section id="CD000493-sec-0132"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0133"> <h6 class="title">Mean gestational age at birth</h6> <p>The mean gestational age for women in the guar gum group was 38.40 weeks and 38.30 weeks for placebo (MD 0.10 weeks, 95% CI −0.73 to 0.93; <a href="./references#CD000493-fig-0031" title="">Analysis 3.5</a>). </p> <p>The following secondary outcomes were not reported for this comparison: caesarean section, postpartum haemorrhage, meconium‐stained liquor, spontaneous or total preterm birth, or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0134"> <h4 class="title">4. Activated charcoal versus no treatment</h4> <p>One trial (<a href="./references#CD000493-bbs2-0012" title="KaajaRJ , KontulaKK , RaihaA , LaatikainenT . Treatment of cholestasis of pregnancy with peroral activated charcoal. a preliminary study. Scandinavian Journal of Gastroenterology1994;29(2):178-81. ">Kaaja 1994</a>) involving 20 women looked at this comparison. </p> <section id="CD000493-sec-0135"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0136"> <h6 class="title">Pruritus</h6> <p>Participants maintained a daily written record of pruritus using four‐point scale. Four (40%) women taking activated charcoal compared with none in the no‐treatment group reported relief of itching after eight days follow‐up. There was little to no difference between groups (RR 9.00, 95% CI 0.55 to 147.95; 20 women; <a href="./references#CD000493-fig-0032" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD000493-sec-0137"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0138"> <h6 class="title">Stillbirth/neonatal death</h6> <p>Outcome not reported.</p> </section> <section id="CD000493-sec-0139"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>Outcome not reported.</p> </section> </section> <section id="CD000493-sec-0140"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0141"> <h6 class="title">Biochemical assessments</h6> <p>After eight days of treatment, seven (70%) women taking activated charcoal compared with one (10%) woman in the no‐treatment group had decreased serum bile acid concentrations (MD −45.20 µmol/L, 95% CI −74.31 to −16.09; 20 women; <a href="./references#CD000493-fig-0033" title="">Analysis 4.2</a>). However, there were few to no differences between charcoal and no treatment in final serum ALT concentrations (MD 74.60, 95% CI −141.33 to 290.53; 20 women; <a href="./references#CD000493-fig-0034" title="">Analysis 4.3</a>). </p> </section> <section id="CD000493-sec-0142"> <h6 class="title">Adverse effects of medication</h6> <p>Some participants reported that they found the charcoal suspension unpleasant to swallow. Some reported that their stools were black (as expected). </p> </section> </section> <section id="CD000493-sec-0143"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0144"> <h6 class="title">Mean gestational age at birth</h6> <p>There was little to no difference in mean gestation at birth between the two groups (MD −1.00 week, 95% CI −2.77 to 0.77; <a href="./references#CD000493-fig-0035" title="">Analysis 4.4</a>). </p> <p>The following secondary outcomes were not reported for this comparison: caesarean section, postpartum haemorrhage, meconium‐stained liquor, spontaneous or total preterm birth, or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0145"> <h4 class="title">5. Dexamethasone versus placebo</h4> <p>One trial (<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>) involving 83 women studied this comparison. </p> <section id="CD000493-sec-0146"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0147"> <h6 class="title">Pruritus</h6> <p>No difference in pruritus score (100 mm VAS) was seen between the dexamethasone and placebo groups after three weeks treatment (83 women; no P value reported). </p> </section> </section> <section id="CD000493-sec-0148"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0149"> <h6 class="title">Stillbirths</h6> <p>One stillbirth was reported in the placebo group and none in the dexamethasone group (RR 0.43, 95% CI 0.02 to 10.31; 83 women; <a href="./references#CD000493-fig-0036" title="">Analysis 5.1</a>). </p> </section> <section id="CD000493-sec-0150"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>Asphyxial events included operative birth due to asphyxia, arterial umbilical pH less than 7.05 and Apgar score of less than seven at five minutes. Four (11%) babies born to women receiving dexamethasone suffered asphyxial events compared with two (4%) babies born to women who received placebo (RR 2.61, 95% CI 0.51 to 13.47; 83 women; <a href="./references#CD000493-fig-0037" title="">Analysis 5.2</a>). </p> </section> <section id="CD000493-sec-0151"> <h6 class="title">Subgroup analysis (bile acid levels ≥ 40 µmol/L versus bile acid levels &lt; 40 µmol/L)</h6> <p><a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> presented data for the subgroups of bile acids equal to or greater than 40 µmol/L versus bile acids less than 40 µmol/L for one of our primary outcomes (fetal distress/asphyxial events) (<a href="./references#CD000493-fig-0038" title="">Analysis 5.3</a>). There were no differences between subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.69, df = 1 (P = 0.40), I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD000493-sec-0152"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0153"> <h6 class="title">Biochemical assessments</h6> <p>Liver function tests were reported only graphically in <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>, as medians and P values. The final serum bile acid concentrations were significantly reduced in the dexamethasone group compared with placebo overall (P = 0.01); and also in the women with severe cholestasis (serum bile acid equal to or greater than 40 µmol/L) (P = 0.01). For serum ALT concentrations, there was not a greater reduction in the dexamethasone group compared with the placebo group overall. </p> </section> <section id="CD000493-sec-0154"> <h6 class="title">Caesarean section</h6> <p><a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> did not report caesarean births but did indicate that rates of elective birth (both caesarean and vaginal) did not differ between the two groups (33% for dexamethasone and 38% for placebo). </p> </section> <section id="CD000493-sec-0155"> <h6 class="title">Adverse effects of medication</h6> <p>One woman on dexamethasone suffered nausea, dizziness and stomach pain. One woman receiving placebo complained of severe headache. </p> </section> </section> <section id="CD000493-sec-0156"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0157"> <h6 class="title">Meconium‐stained liquor</h6> <p>There were few to no differences for meconium‐stained liquor between dexamethasone and placebo (RR 1.00, 95% CI 0.56 to 1.78; 83 women; <a href="./references#CD000493-fig-0039" title="">Analysis 5.4</a>). Similarly, the results were few to no differences in the 'severe' subgroup, with five out of 11 women receiving dexamethasone having meconium‐stained liquor compared with six out of 11 women receiving placebo (RR 0.83, 95% CI 0.36 to 1.94; <a href="./references#CD000493-fig-0039" title="">Analysis 5.4</a>). </p> </section> <section id="CD000493-sec-0158"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>There were few to no differences between dexamethasone and placebo for spontaneous preterm birth at less than 37 weeks' gestation (RR 1.52, 95% CI 0.21 to 10.90; random‐effects analysis: Tau<sup>2</sup> = 1.56; I<sup>2</sup> = 77%; 83 women; <a href="./references#CD000493-fig-0040" title="">Analysis 5.5</a>) or for the subgroup of women with severe (serum bile acid equal to or greater than 40 µmol/L) cholestasis (RR 0.60, 95% CI 0.19 to 1.92; 22 women; <a href="./references#CD000493-fig-0040" title="">Analysis 5.5</a>). There was evidence for a difference between subgroups (test for subgroup differences: Chi<sup>2</sup> = 4.10, df = 1 (P = 0.04), I<sup>2</sup> = 75.6%), suggesting a higher rate of spontaneous preterm birth with dexamethasone for lower bile acid concentrations than for higher concentrations. </p> </section> <section id="CD000493-sec-0159"> <h6 class="title">Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</h6> <p>There were few to no differences between dexamethasone and placebo (RR 1.16, 95% CI 0.26 to 5.10; random‐effects analysis: Tau<sup>2</sup> = 0.88; I<sup>2</sup> = 77%: 83 women; <a href="./references#CD000493-fig-0041" title="">Analysis 5.6</a>). Four of 11 women receiving dexamethasone versus seven of 11 women receiving placebo in the severe subgroup (serum bile acid equal to or greater than 40 µmol/L) had a preterm birth (RR 0.57, CI 0.23 to 1.41; 22 women; <a href="./references#CD000493-fig-0041" title="">Analysis 5.6</a>). There was evidence for a difference between subgroups, (test for subgroup differences: Chi<sup>2</sup> = 4.11, df = 1 (P = 0.04), I<sup>2</sup> = 75.7%), again suggesting a higher rate of spontaneous preterm birth with dexamethasone for lower bile acid concentrations than for higher concentrations. </p> <p>For this comparison the following secondary outcomes were not reported: postpartum haemorrhage, mean gestational age at birth or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0160"> <h4 class="title">6. Ursodeoxycholic acid (UDCA) versus S‐adenosylmethionine (SAMe)</h4> <p>Six trials (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>; <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a>) involving 291 women compared these two interventions. </p> <section id="CD000493-sec-0161"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0162"> <h6 class="title">Pruritus</h6> <p><a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> reported a greater fall in pruritus score on a 0 ‐ 4 scale with both interventions (P &lt; 0.01). Results were analysed as a continuous outcome. Dichotomisation of data for re‐analysis was not possible because results were presented as mean and SD. <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> reported symptomatic improvements in pruritus in both groups, but did not report the actual scores and stated that the differences were not statistically significant. <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> reported symptomatic improvements in pruritus in both groups at one week (MD ‐0.31, 95% CI ‐0.61 to ‐0.01; <a href="./references#CD000493-fig-0043" title="">Analysis 6.2</a>) and two week post‐treatment (MD ‐0.38, 95% CI ‐0.82 to 0.06; <a href="./references#CD000493-fig-0044" title="">Analysis 6.3</a>). </p> <p>The other three trials reported the number of women with improved pruritus after treatment: <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> on a 10‐point scale, and <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a> and <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a> on four‐point scales. Improvements were seen favouring the UDCA group in comparison to the SAMe group in the following categories: any improvement (average RR 1.46, 95% CI 0.83 to 2.59; I<sup>2</sup> = 67%; 3 trials, 117 women); marked improvement (RR 1.73, 95% CI 1.00 to 2.98; 1 trial, 51 women); complete resolution (RR 21.00, 95% CI 1.40 to 315.98; 1 trial, 20 women); and complete resolution or marked improvement (average RR 4.68, 95% CI 0.26 to 83.44; I<sup>2</sup> = 78%; 2 trials, 71 women). However, we found substantial statistical heterogeneity in the analyses for any improvement and complete or marked improvement, so we used a random‐effects model in these analyses. <i>See</i><a href="./references#CD000493-fig-0042" title="">Analysis 6.1</a>. </p> </section> </section> <section id="CD000493-sec-0163"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0164"> <h6 class="title">Stillbirth/neonatal death</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> reported zero stillbirths in either group and <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> and <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> reported zero perinatal deaths in either group. Three trials (<a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>) did not comment on this outcome. </p> </section> <section id="CD000493-sec-0165"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>For <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, we included those women who delivered by caesarean section for suspected fetal asphyxia, to avoid duplication and overestimation of rates of fetal distress. For <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>, we included women with babies who had an Apgar score of less than seven at five minutes in our analysis. <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a> reported that none of the babies had Apgar scores less than seven at five minutes. Overall, there were few to no differences in fetal distress between the two groups (RR 0.94, 95% CI 0.25 to 3.58; 3 trials, 117 women; <a href="./references#CD000493-fig-0045" title="">Analysis 6.4</a>). </p> </section> </section> <section id="CD000493-sec-0166"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0167"> <h6 class="title">Biochemical assessments</h6> <p>Women taking UDCA in <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> had a greater fall in serum bile acid concentrations compared with women taking SAMe (MD 12.90 µmol/L, 95% CI 4.36 to 21.44; 16 women; <a href="./references#CD000493-fig-0046" title="">Analysis 6.5</a>). <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> reported a lower serum bile acid concentration in the UDCA group compared with the SAMe group after treatment (MD −27.00 µmol/L, 95% CI −43.67 to −10.33; 51 women; <a href="./references#CD000493-fig-0046" title="">Analysis 6.5</a>). </p> <p>Serum ALT concentrations were lower with SAMe (MD ‐2.20 U/L, 95% CI −3.55 to −0.85; 51 women; <a href="./references#CD000493-fig-0047" title="">Analysis 6.6</a>). </p> <p><a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a> reported differences in laboratory variables as median and P values in relation to treatment. A reduction was reported in serum bile acids (P = 0.001), and serum ALT (P = 0.001) in the group receiving UDCA, while the changes from baseline were not significant in the group receiving SAMe. All liver function results in <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a> were presented graphically: after 15 days treatment, women in the UDCA group showed lower serum total bile acid concentrations compared with women in the SAMe group (P &lt; 0.05) and there were no differences seen for serum ALT concentrations after 15 days treatment with either UDCA or SAMe (20 women in total). <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> (79 women) found no difference in serum bile acids between the two groups (<a href="./references#CD000493-fig-0046" title="">Analysis 6.5</a>). </p> <p><a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> is published in abstract form only. It is reported in the abstract that no differences in total bile acid(TBA), alanine aminotransferase, aspartate aminotransferase, and total bilirubin were observed between the groups. </p> </section> <section id="CD000493-sec-0168"> <h6 class="title">Caesarean section</h6> <p>Four trials reported caesarean sections, with few to no difference seen between those women randomised to UDCA and those randomised to SAMe (RR 0.86, 95% CI 0.65 to 1.13; 4 trials, 196 women; <a href="./references#CD000493-fig-0048" title="">Analysis 6.7</a>). </p> </section> <section id="CD000493-sec-0169"> <h6 class="title">Postpartum haemorrhage</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> and <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a> reported estimated blood loss (mL) at birth rather than the incidence of postpartum haemorrhage. Differences between the groups were not apparent. </p> </section> <section id="CD000493-sec-0170"> <h6 class="title">Adverse effects of medication</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, <a href="./references#CD000493-bbs2-0021" title="RoncagliaN , ArreghiniA , LocatelliA , BelliniP , AndreottiC , GhidiniA . Obstetric cholestasis: outcome with active management. European Journal of Obstetrics and Gynaecology and Reproductive Biology2002;100(2):167-70. RoncagliaN , LocatelliA , ArreghiniA , AssiF , CameroniI , PezzulloJC , et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of gestational cholestasis. BJOG: an international journal of obstetrics and gynaecology2004;111(1):17-21. RoncagliaN , LocatelliA , BelliniP , ArreghiniA , AndreottiC , GhidiniA . A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis [abstract]. American Journal of Obstetrics and Gynecology2000;182(1 pt 2):S167. ">Roncaglia 2004</a>, <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> and <a href="./references#CD000493-bbs2-0026" title="ZhangL , LiuXH , QiHB , LiZ , FuXD , ChenL , et al. Ursodeoxycholic acid and s-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial. European Review for Medical and Pharmacological Sciences2015;19(19):3770-6. ">Zhang 2015</a> noted no adverse effects on women or babies with either therapy. <a href="./references#CD000493-bbs2-0006" title="FloreaniA , PaternosterD , MelisA , GrellaPV . S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. European Journal of Obstetrics and Gynecology1996;67(2):109-3. FloreaniA , PaternosterD , MelisA , ZappalaF , ChiaramonteM , GrellaPV . A controlled trial with S-adenosylmethionine versus ursodeoxycholic acid in intrahepatic cholestasis of pregnancy [EASL abstract]. Journal of Hepatology1996;25 Suppl 1:S136. ">Floreani 1996</a> noted that both drugs were "well tolerated". </p> </section> </section> <section id="CD000493-sec-0171"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0172"> <h6 class="title">Meconium‐stained liquor</h6> <p>Three trials compared the observation of meconium‐stained liquor at birth, with a 67% reduction in those women randomised to UDCA compared with those randomised to SAMe (RR 0.33, 95% CI 0.20 to 0.56; 3 trials, 176 women; <a href="./references#CD000493-fig-0049" title="">Analysis 6.8</a>). </p> </section> <section id="CD000493-sec-0173"> <h6 class="title">Mean gestational age at birth</h6> <p>There was little to no difference in gestational age at birth between those women randomised to UDCA and those randomised to SAMe in two trials (MD −0.04 weeks, 95% CI −0.84 to 0.76; 2 trials, 66 women; <a href="./references#CD000493-fig-0050" title="">Analysis 6.9</a>). </p> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> only reported ranges and no SD (no large differences were seen between UDCA and SAMe). </p> </section> <section id="CD000493-sec-0174"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>No important differences between UDCA and SAMe were seen in two trials for the incidence of spontaneous births at less than 37 weeks (RR 0.59, 95% 0.22 to 1.59; 2 trials, 62 women; <a href="./references#CD000493-fig-0051" title="">Analysis 6.10</a>). </p> </section> <section id="CD000493-sec-0175"> <h6 class="title">Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</h6> <p>Three other trials reported the total number of births at less than 37 weeks of gestation for the two groups, but did not specify how many of them were spontaneous preterm births. There was a 46% reduction in total preterm births in the UDCA group (RR 0.54, 95% CI 0.35 to 0.81; 3 trials, 150 women; <a href="./references#CD000493-fig-0052" title="">Analysis 6.11</a>). </p> </section> <section id="CD000493-sec-0176"> <h6 class="title">Admission to neonatal unit</h6> <p>Three trials reported the number of babies that were admitted to the neonatal unit, with little to no difference between groups (RR 0.56, 95% CI 0.26 to 1.20; 3 trials, 176 babies; <a href="./references#CD000493-fig-0053" title="">Analysis 6.12</a>). </p> </section> </section> </section> <section id="CD000493-sec-0177"> <h4 class="title">7. Ursodeoxycholic acid (UDCA) versus dexamethasone</h4> <p>One study (<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>) involving 83 women compared these two interventions. </p> <section id="CD000493-sec-0178"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0179"> <h6 class="title">Pruritus</h6> <p>Improvement in pruritus after three weeks of treatment was reported graphically. No differences were seen overall, although in the subgroup with severe cholestasis (serum bile acid equal to or greater than 40 µmol/L), UDCA was more effective in reducing pruritus than dexamethasone (P = 0.01). </p> </section> </section> <section id="CD000493-sec-0180"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0181"> <h6 class="title">Stillbirth/neonatal death</h6> <p>There were no stillbirths or neonatal deaths in either group.</p> </section> <section id="CD000493-sec-0182"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>There was no difference in fetal asphyxial events between the UDCA and the dexamethasone groups (RR 0.34, 95% CI 0.08 to 1.45; 83 women; <a href="./references#CD000493-fig-0054" title="">Analysis 7.1</a>). </p> </section> <section id="CD000493-sec-0183"> <h6 class="title">Subgroup analysis (serum bile acid concentrations ≥ 40 µmol/L versus serum bile acid concentrations &lt; 40 µmol/L) </h6> <p><a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> presented data for the subgroups of women with serum bile acids equal to or greater than 40 µmol/L versus those with serum bile acids less than 40 µmol/L for fetal distress/asphyxial events. In the severe subgroup (serum bile acids equal to or greater than 40 µmol/L), none of 12 in the UDCA group and one of 11 in the dexamethasone group were reported to have fetal asphyxial events (RR 0.31, 95% CI 0.01 to 6.85; 23 women; <a href="./references#CD000493-fig-0054" title="">Analysis 7.1</a>). There were few to no differences between subgroups (<a href="./references#CD000493-fig-0054" title="">Analysis 7.1</a>) (test for subgroup differences: Chi<sup>2</sup> = 0.01, df = 1 (P = 0.93), I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD000493-sec-0184"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0185"> <h6 class="title">Biochemical assessments</h6> <p>UDCA was better than dexamethasone in reducing serum bile acid (P = 0.001) and serum ALT (P = 0.01) concentrations. In the subgroup of women with severe cholestasis (serum bile acids equal to or greater than 40 µmol/L), these analyses showed greater reductions for UDCA compared with dexamethasone. These results were reported as graphs and P values. </p> </section> <section id="CD000493-sec-0186"> <h6 class="title">Caesarean section</h6> <p><a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a> did not report caesarean births but did indicate that rates of elective birth (both caesarean and vaginal) did not differ between the two groups (32% for UDCA and 33% for dexamethasone). </p> </section> <section id="CD000493-sec-0187"> <h6 class="title">Adverse effects of medication</h6> <p>One woman on UDCA complained of diarrhoea, while one woman receiving dexamethasone suffered from nausea, dizziness and stomach pain (RR 0.77, 95% CI 0.05 to 11.83; 83 women; <a href="./references#CD000493-fig-0055" title="">Analysis 7.2</a>). </p> </section> </section> <section id="CD000493-sec-0188"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0189"> <h6 class="title">Meconium‐stained liquor</h6> <p>There was little to no difference between UDCA and dexamethasone in the observation of meconium‐stained liquor (RR 1.06, 95% CI 0.60 to 1.87; 83 women; <a href="./references#CD000493-fig-0056" title="">Analysis 7.3</a>). In the severe subgroup, six of 12 women in the UDCA group and five of 11 in the dexamethasone group were reported to have meconium‐stained liquor. </p> </section> <section id="CD000493-sec-0190"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>There was little to no difference in spontaneous preterm birth between women taking UDCA and women taking dexamethasone (RR 0.68, 95% CI 0.29 to 1.59; 83 women; <a href="./references#CD000493-fig-0057" title="">Analysis 7.4</a>). In the severe subgroup, four of 12 women in the UDCA group and four of 11 in the dexamethasone group had a spontaneous preterm birth. </p> </section> <section id="CD000493-sec-0191"> <h6 class="title">Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</h6> <p>There were few to no differences between groups (RR 0.87, 95% CI 0.44 to 1.71; 83 women; <a href="./references#CD000493-fig-0058" title="">Analysis 7.5</a>). In the severe subgroup, six of 12 women in the UDCA group and four of 11 in the dexamethasone group had a preterm birth ((RR 1.38, 95% CI 0.52 to 3.61; <a href="./references#CD000493-fig-0058" title="">Analysis 7.5</a>.2). </p> <p>The following secondary outcomes were not reported: postpartum haemorrhage, mean gestational age at birth or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0192"> <h4 class="title">8. Ursodeoxycholic acid (UDCA) versus cholestyramine</h4> <p>One trial (<a href="./references#CD000493-bbs2-0013" title="KondrackieneJ , BeuersU , KupcinskasL . Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology2005;129(3):894-901. KondrackieneJ , KupcinskasL , SumskieneJ . Efficacy of moderate doses of ursodeoxycholic acid in comparison to cholestyramine in the treatment of intrahepatic cholestasis of pregnancy [abstract]. Journal of Hepatology2001;34(1):186. ">Kondrackiene 2005</a>) involving 84 women compared these two interventions. </p> <section id="CD000493-sec-0193"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0194"> <h6 class="title">Pruritus</h6> <p>Self‐assessment of pruritus was performed by participants on a 0 ‐ 4 scale. Pruritus was relieved after three to four days in the UDCA group compared with seven to 10 days for the cholestyramine group. UDCA was found to result in a lower mean pruritus score compared with cholestyramine. After four days, the pruritus score was lower in the group receiving UDCA compared with the group receiving cholestyramine (P &lt; 0.05 after four days; P &lt; 0.001 after 14 days). Results were presented as mean and SD, and dichotomisation was not possible. A higher number of women in the UDCA group reported a reduction in pruritus score by more than 50% (RR 3.50, 95% CI 1.81 to 6.77; 84 women; <a href="./references#CD000493-fig-0059" title="">Analysis 8.1</a>). </p> </section> </section> <section id="CD000493-sec-0195"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0196"> <h6 class="title">Stillbirth/neonatal death</h6> <p>In this single trial there were no stillbirths or neonatal deaths in either group.</p> </section> <section id="CD000493-sec-0197"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>One out of 42 women in each group suffered morbidity associated with fetal distress (RR 1.00, 95% CI 0.06 to 15.47; 84 women; <a href="./references#CD000493-fig-0060" title="">Analysis 8.2</a>). </p> </section> </section> <section id="CD000493-sec-0198"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0199"> <h6 class="title">Liver function</h6> <p>The trial did not find any differences in serum bile acid concentrations between the two groups after treatment (MD −1.80 µmol/L, 95% CI −13.10 to 9.50; 84 women; <a href="./references#CD000493-fig-0061" title="">Analysis 8.3</a>). For serum ALT, women in the UDCA group had much lower concentrations after treatment than women in the cholestyramine group (MD −144.20 U/L, 95% CI −186.63 to −101.77; 84 women; <a href="./references#CD000493-fig-0062" title="">Analysis 8.4</a>). </p> </section> <section id="CD000493-sec-0200"> <h6 class="title">Caesarean section</h6> <p>There were few to no differences between the two groups in rates of caesarean section (RR 2.33, 95% CI 0.65 to 8.42; 84 women; <a href="./references#CD000493-fig-0063" title="">Analysis 8.5</a>). Reasons for the seven caesarean sections in the UDCA group were: three multiple pregnancies, one placenta praevia, one cephalo‐pelvic disproportion, one fetal distress and one advanced maternal age. The three caesarean sections in the cholestyramine group were performed for: fetal distress, twin pregnancy and cephalo‐pelvic disproportion (one case each). </p> </section> <section id="CD000493-sec-0201"> <h6 class="title">Adverse effects of medication</h6> <p>Cholestyramine use was found to have a greater number of adverse effects, with 12 out of 42 women suffering adverse effects (11 women suffering nausea, five women suffering vomiting and one woman suffering diarrhoea), compared with no adverse events reported for women taking UDCA (RR 0.04, 95% CI 0.00 to 0.65; <a href="./references#CD000493-fig-0064" title="">Analysis 8.6</a>). </p> </section> </section> <section id="CD000493-sec-0202"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0203"> <h6 class="title">Mean gestational age at birth</h6> <p>Women receiving UDCA had a shorter gestational length than women in the cholestyramine group (MD −1.30 weeks, 95% CI −1.99 to −0.61: 1 trial; 84 women; <a href="./references#CD000493-fig-0065" title="">Analysis 8.7</a>). </p> </section> <section id="CD000493-sec-0204"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>The study did not report spontaneous preterm births separately for the two interventions.</p> </section> <section id="CD000493-sec-0205"> <h6 class="title">Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</h6> <p>There was little to no difference for preterm births between the two groups (RR 0.60, 95% CI 0.15 to 2.35; 84 women; <a href="./references#CD000493-fig-0066" title="">Analysis 8.8</a>). </p> <p>The following secondary outcomes were not reported: postpartum haemorrhage, meconium‐stained liquor or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0206"> <h4 class="title">9. Ursodeoxycholic acid plus S‐adenosylmethionine (UDCA+SAMe) versus placebo</h4> <p>One trial (<a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>) in 16 women contributed data to this comparison. </p> <section id="CD000493-sec-0207"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0208"> <h6 class="title">Pruritus</h6> <p>Pruritus was assessed on a 0 ‐ 4 scale and results were analysed as a continuous outcome. Dichotomisation of data for re‐analysis was not possible, because results were presented as mean and SD. Significant change in pruritus score from the baseline was reported after treatment in the two groups (P &lt; 0.01). </p> </section> </section> <section id="CD000493-sec-0209"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0210"> <h6 class="title">Stillbirth/neonatal death</h6> <p>This outcome was not reported.</p> </section> <section id="CD000493-sec-0211"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>This outcome was not reported.</p> </section> </section> <section id="CD000493-sec-0212"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0213"> <h6 class="title">Biochemical assessments</h6> <p>Compared with women given placebo, women given UDCA + SAMe had greater decreases in serum bile acids (MD 41.70 µmol/L, 95% CI 35.57 to 47.83; 16 women; <a href="./references#CD000493-fig-0067" title="">Analysis 9.1</a>). </p> </section> <section id="CD000493-sec-0214"> <h6 class="title">Adverse effects of medication</h6> <p>No adverse effects were observed in the mothers or the babies in either group.</p> </section> </section> <section id="CD000493-sec-0215"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0216"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>One case of spontaneous preterm birth was reported in the UDCA + SAMe group compared with none in the placebo group in <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>. </p> <p>The following secondary outcomes were not reported: caesarean section, postpartum haemorrhage, meconium‐stained liquor, mean gestational age at birth, total preterm birth or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0217"> <h4 class="title">10. Ursodeoxycholic acid plus S‐adenosylmethionine (UDCA+SAMe) versus S‐adenosylmethionine (SAMe) </h4> <p>Three trials (147 women) contributed data to this comparison (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>). </p> <section id="CD000493-sec-0218"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0219"> <h6 class="title">Pruritus</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> reported no difference for any improvement in pruritus on a 10‐point scale between the two groups (RR 1.42, 95% CI 0.99 to 2.03; 52 women). However, when restricted only to women with marked improvement, more women in the UDCA + SAMe group reported a marked improvement in pruritus compared with those in the SAMe‐alone group (RR 1.85, 95% CI 1.09 to 3.14; 52 women; <a href="./references#CD000493-fig-0068" title="">Analysis 10.1</a>). </p> <p><a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> reported a reduction in pruritus after treatment with UDCA + SAMe compared with SAMe alone. They used a 0 ‐ 4 scale for assessing pruritus but analysed results as a continuous outcome. Dichotomisation of data and re‐analysis was not possible because results were reported as mean and SD. <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> reported improvements in pruritus symptoms in both groups but did not report the actual scores, and stated that the differences were not statistically significant. </p> </section> </section> <section id="CD000493-sec-0220"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0221"> <h6 class="title">Stillbirth/neonatal death</h6> <p>There were no stillbirths or neonatal deaths in <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> or <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> (<a href="./references#CD000493-fig-0069" title="">Analysis 10.2</a>). This outcome was not reported in <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>. </p> </section> <section id="CD000493-sec-0222"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>In <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, one woman (4%) in the UDCA + SAMe group and three (12%) in the SAMe‐alone group had an operative birth for suspected fetal asphyxia (RR 0.31, 95% CI 0.03 to 2.78; 52 women; <a href="./references#CD000493-fig-0070" title="">Analysis 10.3</a>). </p> </section> </section> <section id="CD000493-sec-0223"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0224"> <h6 class="title">Biochemical assessments</h6> <p>Two trials reported contrasting results for improvement in bile acid concentrations. <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> found that serum bile acids after three to four weeks were lower in the UDCA + SAMe group compared with the SAMe‐alone group (MD −25.00 µmol/L, 95% CI −40.16 to −9.84; 52 women). In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, reduction in serum bile acid concentrations were lower in the SAMe‐alone group compared with the UDCA + SAMe group after 20 days (MD 24.20 µmol/L, 95% CI 16.43 to 31.97; 16 women; <a href="./references#CD000493-fig-0071" title="">Analysis 10.4</a>). </p> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> was the only trial to report serum ALT concentrations after treatment, which were lower after treatment with UDCA + SAMe compared with SAMe‐alone (MD −141 U/L, 95% CI −3.59 to −1.21; 52 women; <a href="./references#CD000493-fig-0072" title="">Analysis 10.5</a>). </p> </section> <section id="CD000493-sec-0225"> <h6 class="title">Caesarean section</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> found little to no difference between the UDCA + SAMe group compared with the SAMe‐alone group for caesareans (RR 0.37, 95% CI 0.08 to 1.74, 52 women; <a href="./references#CD000493-fig-0073" title="">Analysis 10.6</a>). </p> </section> <section id="CD000493-sec-0226"> <h6 class="title">Postpartum haemorrhage</h6> <p>The three trials did not report the incidence of postpartum haemorrhage. <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> compared the estimated blood loss at delivery, which was 296 mL in the UDCA + SAMe group compared with 295 mL in the SAMe‐alone group (MD 1.00, 95% CI −76.75 to 78.75; 52 women; <a href="./references#CD000493-fig-0074" title="">Analysis 10.7</a>). </p> </section> <section id="CD000493-sec-0227"> <h6 class="title">Adverse effects of medication</h6> <p>Neither <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> nor <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> reported on adverse events. <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> reported that no adverse drug reactions were observed. </p> </section> </section> <section id="CD000493-sec-0228"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0229"> <h6 class="title">Meconium‐stained liquor</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> found no differences between the UDCA + SAMe and the SAMe‐alone groups for observation of meconium‐stained liquor (RR 0.46, 95% CI 0.09 to 2.31; 52 women; <a href="./references#CD000493-fig-0075" title="">Analysis 10.8</a>). </p> </section> <section id="CD000493-sec-0230"> <h6 class="title">Mean gestational age at birth</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> indicated that this outcome did not differ significantly between the UDCA + SAMe and the SAMe‐alone groups, but did not report mean (and SD) gestational age at birth. </p> </section> <section id="CD000493-sec-0231"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p><a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> reported three cases of spontaneous preterm labour in the SAMe‐alone group compared with one in the UDCA + SAMe group (RR 0.33, 95% CI 0.04 to 2.56; 16 women; <a href="./references#CD000493-fig-0076" title="">Analysis 10.9</a>). </p> </section> <section id="CD000493-sec-0232"> <h6 class="title">Total preterm births at less than 37 weeks (spontaneous and iatrogenic) ‐ not a prespecified outcome </h6> <p>In <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, the rate of preterm birth at less than 36 weeks was 28% (7/25) in the SAMe‐alone group compared with 15% (4/27) in the UDCA + SAMe group at less than 36 weeks (RR 0.53, 95% CI 0.18 to 1.59; 52 women; <a href="./references#CD000493-fig-0077" title="">Analysis 10.10</a>). </p> </section> <section id="CD000493-sec-0233"> <h6 class="title">Admission to neonatal unit</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> reported few to no differences between UDCA + SAMe and the SAMe‐alone groups for admission to the neonatal unit (RR 0.46, 95% CI 0.09 to 2.31; 52 women; <a href="./references#CD000493-fig-0078" title="">Analysis 10.11</a>). </p> </section> </section> </section> <section id="CD000493-sec-0234"> <h4 class="title">11. Ursodeoxycholic acid plus S‐adenosylmethionine (UDCA+SAMe) versus ursodeoxycholic acid (UDCA) </h4> <p>Five trials (295 women) contributed data to this comparison (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>). </p> <section id="CD000493-sec-0235"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0236"> <h6 class="title">Pruritus</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> reported the effect of treatment on pruritus as deterioration, not affected, mild improvement and marked improvement. Few to no differences were seen between the UDCA + SAMe and the UDCA‐alone groups for improvement in pruritus, either for any improvement (RR 1.05, 95% CI 0.83 to 1.35; 53 women) or a marked improvement (RR 1.07, 95% CI 0.76 to 1.50; 53 women; <a href="./references#CD000493-fig-0079" title="">Analysis 11.1</a>). </p> <p><a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> used a 0 ‐ 4 scale for assessing pruritus and analysed results as a continuous outcome, which may not be the appropriate analysis. They found a reduction in pruritus score for the UDCA + SAMe group compared with the UDCA‐alone group. <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a> reported mean itching score (0 ‐ 4 scale) as mean and SD before and after treatment, and we were therefore unable to include this in the meta‐analysis. The results reported were: UDCA + SAMe 'before treatment' 3.89 ± 1.52, 'after treatment' 1.12 ± 0.63; UDCA 'before treatment' 3.90 ± 1.43, 'after treatment' 2.78 ± 0.79. <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> reported improvements in pruritus symptoms in both groups, but did not report the actual scores and stated that the differences were not statistically significant. <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> found a small difference in pruritus score associated with UDCA + SAMe treatment versus UDCA‐alone treatment (MD −0.41, 95% CI −0.66 to −0.16; 80 women; <a href="./references#CD000493-fig-0080" title="">Analysis 11.2</a>). </p> </section> </section> <section id="CD000493-sec-0237"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0238"> <h6 class="title">Stillbirth/neonatal death</h6> <p>There were no stillbirths or neonatal deaths in <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> or <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a> (<a href="./references#CD000493-fig-0081" title="">Analysis 11.3</a>). The other three trials (<a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>) did not report this outcome. </p> </section> <section id="CD000493-sec-0239"> <h6 class="title">Fetal distress/asphyxial events</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> and <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> reported on this, finding a reduction in events in the UDCA + SAMe group (RR 0.14, 95% CI 0.03 to 0.76; 2 trials, 133 women; <a href="./references#CD000493-fig-0082" title="">Analysis 11.4</a>)<i>.</i><a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a> prespecified an Apgar score of seven or lower as one of the perinatal outcomes, but these data were either not reported or not translated. </p> </section> </section> <section id="CD000493-sec-0240"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0241"> <h6 class="title">Biochemical assessments</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> found no difference between the UDCA + SAMe and the UDCA‐alone groups for serum bile acid concentrations (MD 2.00 µmol/L, 95% CI −11.71 to 15.71; 53 women) after treatment, whereas <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a> did find a reduction in serum bile acid concentrations in women taking UDCA (MD 11.30 µmol/L, 95% CI 2.16 to 20.44; 16 women; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> found a reduction in serum bile acid concentrations with UDCA + SAMe (MD −33.40 µmol/L, 95% CI −34.87 to −31.93; 80 women) <a href="./references#CD000493-fig-0083" title="">Analysis 11.5</a>). The extremely high heterogeneity (I<sup>2</sup> of 96%) in analysis 11.5 may be largely due to the trial by <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> which showed a larger reduction in bile acids and a very narrow standard deviation. Since this trial was reported only in abstract and classed as low quality these results should be interpreted with caution. </p> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> found lower concentrations of serum aminotransferase (ALT) after treatment with combined therapy (MD −2.40 U/L, 95% CI −3.59 to −1.21; 52 women; <a href="./references#CD000493-fig-0084" title="">Analysis 11.6</a>). </p> <p><a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a> reported a greater reduction with combined therapy (MD 1.28 IU/L, 95% CI 1.15 to 1.41; 64 women). </p> <p>Two studies (<a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a>) found a reduction in serum alanine aminotransferase (ALT) with UDCA + SAMe compared with UDCA‐alone (MD 1.28, 95% CI 1.15 to 1.41; 144 women; <a href="./references#CD000493-fig-0085" title="">Analysis 11.7</a>) </p> </section> <section id="CD000493-sec-0242"> <h6 class="title">Caesarean section</h6> <p>Three trials reported this outcome. The rates of caesarean section were lower in the UDCA + SAMe group compared with UDCA‐alone (RR 0.50, 95% CI 0.35 to 0.73; 196 women; <a href="./references#CD000493-fig-0086" title="">Analysis 11.8</a>). </p> </section> <section id="CD000493-sec-0243"> <h6 class="title">Postpartum haemorrhage</h6> <p><a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> reported the incidence of postpartum haemorrhage. There was a reduction in postpartum haemorrhage in the UDCA + SAMe group compared with the UDCA‐alone group (RR 0.41, 95% CI 0.22 to 0.78; 80 women). </p> </section> <section id="CD000493-sec-0244"> <h6 class="title">Adverse effects of medication</h6> <p>There were no adverse effects reported in the three studies (<a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>). <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a> and <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> did not report this outcome. </p> </section> </section> <section id="CD000493-sec-0245"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0246"> <h6 class="title">Meconium‐stained liquor</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> and <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> reported a reduction in meconium‐stained liquor associated with UDCA + SAMe compared with UDCA‐alone (RR 0.55, 95 CI 0.34 to 0.88; 2 trials, 133 women; <a href="./references#CD000493-fig-0088" title="">Analysis 11.10</a>). <a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a> prespecified this outcome but data were not reported or translated. </p> </section> <section id="CD000493-sec-0247"> <h6 class="title">Mean gestational age at birth</h6> <p>Three trials did not report mean gestation at birth with SDs (<a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a>; <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>; <a href="./references#CD000493-bbs2-0025" title="ZhangL , QiHB , LiZ , FuXD , ChenL . Multicenter randomized prospective controlled study of ursodeoxycholic acid and s-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S526. ">Zhang 2012</a>). <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> and <a href="./references#CD000493-bbs2-0023" title="SunGY , XuY , ZhangM . Ursodeoxycholic acid combined with S-adenosylmethionine for treatment of severe intrahepatic cholestasis of pregnancy. World Chinese Journal of Digestology2014;22(26):3994-8. ">Sun 2014</a> indicated that this outcome did not differ significantly between the two groups. </p> </section> <section id="CD000493-sec-0248"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>In <a href="./references#CD000493-bbs2-0017" title="NicastriPL , DiaferiaA , TartagniM , LoizziP , FanelliM . A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. British Journal of Obstetrics and Gynaecology1998;105(11):1205-7. ">Nicastri 1998</a>, one woman who received UDCA + SAMe and two women who received UDCA‐alone went into spontaneous labour at less than 37 weeks' gestation (RR 0.50, 95% CI 0.06 to 4.47; 16 women; <a href="./references#CD000493-fig-0089" title="">Analysis 11.11</a>). </p> </section> <section id="CD000493-sec-0249"> <h6 class="title">Total preterm birth at less than 37 weeks (spontaneous and iatrogenic)</h6> <p><a href="./references#CD000493-bbs2-0016" title="LuoDH . Clinical observation on the effect on of Transmetil combined with ursodeoxycholic acid for intrahepatic cholestasis of pregnancy. Xian Dai Zhong Xi Yi Jie He Za Zhi [Modern Journal of Integrated Traditional Chinese and Western Medicine]2008;17(7):1011-2. ">Luo 2008</a> found few to no differences for total preterm births at less than 37 weeks' gestation between the two groups (RR 0.69, 95% CI 0.29 to 1.62; 64 women; <a href="./references#CD000493-fig-0090" title="">Analysis 11.12</a>). In <a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a>, the total preterm birth rate (&lt; 36 weeks) was 15% in both groups. </p> </section> <section id="CD000493-sec-0250"> <h6 class="title">Admission to neonatal unit</h6> <p><a href="./references#CD000493-bbs2-0001" title="BinderT , SalajP , ZimaT , VitekL . Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. Journal of Perinatal Medicine2006;34:383-91. BinderT , SalajP , ZinaT , VitekL . [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]. Ceska Gynekologie2006;71(2):92-8. ">Binder 2006</a> reported that two babies in the UDCA + SAMe group were admitted to neonatal intensive care unit for moderate respiratory distress syndrome (RDS), and that three babies in the UDCA‐alone group (severe prematurity in one baby and for RDS in two babies) were admitted to the neonatal unit (RR 0.64, 95% CI 0.12 to 3.54; 53 babies; <a href="./references#CD000493-fig-0091" title="">Analysis 11.13</a>). </p> </section> </section> </section> <section id="CD000493-sec-0251"> <h4 class="title">12. Ursodeoxycholic acid (UDCA) and Salvia versus UDCA (ursodeoxycholic acid)</h4> <p>One trial (<a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a>) (128 women) contributed data to this comparison. </p> <section id="CD000493-sec-0252"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0253"> <h6 class="title">Pruritus</h6> <p>Reduction in pruritus on a 0 ‐ 4 scale from moderate/severe to mild pruritus (3.6 to 1.4) was reported in 58 of 72 (80.5%) women in the UDCA + salvia group compared with 43 of 56 (76.7%) in the UDCA‐alone group, showing no difference (RR 1.05, 95% CI 0.87 to 1.26; 128 women; <a href="./references#CD000493-fig-0092" title="">Analysis 12.1</a>). These effects were seen within four to six days in UDCA + salvia group and eight to 10 days in the UDCA‐alone group. </p> </section> </section> <section id="CD000493-sec-0254"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0255"> <h6 class="title">Stillbirth/neonatal death</h6> <p>The study did not report this outcome.</p> </section> <section id="CD000493-sec-0256"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>Thirteen women in the combination group and 11 women in the UDCA‐alone group had caesarean births due to fetal distress. There was little to no difference <i>(</i>RR 0.92, 95% CI 0.45 to 1.89; 128 women; <a href="./references#CD000493-fig-0095" title="">Analysis 12.4</a>) </p> </section> </section> <section id="CD000493-sec-0257"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0258"> <h6 class="title">Biochemical assessments</h6> <p><a href="./references#CD000493-bbs2-0005" title="FangJ , GouWL , LiQL . Effect of integrative Chinese and Western medicine in treating pregnant women with intrahepatic cholestasis. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi [Journal of Integrated Traditional and Western Medicine]2009;29(10):869-71. ">Fang 2009</a> found a reduction in the concentrations of serum ALT after treatment with UDCA + salvia compared with UDCA‐alone ((MD −14.90 µmol/L, 95% CI −24.42 to −5.38; 128 women; <a href="./references#CD000493-fig-0093" title="">Analysis 12.2</a>). Data on serum bile acids were not available. </p> </section> </section> <section id="CD000493-sec-0259"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0260"> <h6 class="title">Meconium‐stained liquor</h6> <p>No differences between UDCA + salvia and UDCA‐alone were seen for meconium‐stained liquor (RR 0.86, 95 CI 0.38 to 1.98; 128 women; <a href="./references#CD000493-fig-0094" title="">Analysis 12.3</a>). </p> <p>The following secondary outcomes were not reported: caesarean section (although caesarean births performed for fetal distress were reported, caesarean section for other indications were not reported), postpartum haemorrhage, adverse effects of medication, mean gestational age at birth, spontaneous preterm birth, total preterm birth or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0261"> <h4 class="title">13. Yinchenghao decoction (YCHD) versus S‐adenosylmethionine (SAMe)</h4> <p>One trial (<a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a>) (60 women) contributed data to this comparison. </p> <section id="CD000493-sec-0262"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0263"> <h6 class="title">Pruritus</h6> <p><a href="./references#CD000493-bbs2-0010" title="HuangJY , LiuH . Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy. Chinese Journal of Integrated Traditional &amp; Western Medicine2004;24(4):309-11. ">Huang 2004</a> demonstrated few to no differences between YCHD and SAMe in improving the degree of pruritus after treatment (RR 1.00, 95% CI 0.77 to 1.29; 60 women; <a href="./references#CD000493-fig-0096" title="">Analysis 13.1</a>) as measured by the symptom of itching appraisal score pre‐ and post‐treatment. </p> </section> </section> <section id="CD000493-sec-0264"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0265"> <h6 class="title">Stillbirth/neonatal death</h6> <p>There were no stillbirths or neonatal deaths in either group.</p> </section> <section id="CD000493-sec-0266"> <h6 class="title">Fetal distress/asphyxial events</h6> <p>No difference in asphyxial events was found between the two groups (RR 0.86, 95% CI 0.29 to 2.50; 60 women; <a href="./references#CD000493-fig-0098" title="">Analysis 13.3</a>). </p> </section> </section> <section id="CD000493-sec-0267"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0268"> <h6 class="title">Biochemical assessments</h6> <p>There was little to no difference in the concentrations of glycocholic acid (a constituent of serum bile acids) (MD −1.50, 95% CI −6.12 to 3.12; 60 women; <a href="./references#CD000493-fig-0099" title="">Analysis 13.4</a>) or of ALT (MD 3.40, 95% CI −12.37 to 19.17; 60 women; <a href="./references#CD000493-fig-0100" title="">Analysis 13.5</a>) when comparing the two intervention groups. </p> </section> <section id="CD000493-sec-0269"> <h6 class="title">Caesarean section</h6> <p>No differences were seen between the YCHD and SAMe groups for caesarean section (RR 0.93, 95% CI 0.56 to 1.55; 60 women; <a href="./references#CD000493-fig-0101" title="">Analysis 13.6</a>). </p> </section> </section> <section id="CD000493-sec-0270"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0271"> <h6 class="title">Meconium‐stained liquor</h6> <p>No differences were found between YCHD and SAMe for meconium‐stained liquor (RR 0.86, 95% CI 0.29 to 2.50; 60 women; <a href="./references#CD000493-fig-0102" title="">Analysis 13.7</a>). </p> </section> <section id="CD000493-sec-0272"> <h6 class="title">Mean gestational age at birth</h6> <p>Mean gestational age at birth was 38.1 in the YCHD group and 37.4 weeks in the SAMe group. There was little difference between the two groups (MD 0.70 weeks, 95% CI −0.35 to 1.75; <a href="./references#CD000493-fig-0103" title="">Analysis 13.8</a>). </p> <p>The following secondary outcomes were not reported: postpartum haemorrhage, adverse effects of medication, spontaneous preterm birth, total preterm birth or admission to neonatal unit. </p> </section> </section> </section> <section id="CD000493-sec-0273"> <h4 class="title">14. Danxioling versus Yiganling</h4> <p>One trial (<a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a>) (58 women) contributed data to this comparison. </p> <section id="CD000493-sec-0274"> <h5 class="title">Primary outcomes (maternal)</h5> <section id="CD000493-sec-0275"> <h6 class="title">Pruritus</h6> <p>All participants (29 women in each group) noticed improvement in pruritus after treatment (MD 1.00, 95% CI 0.94 to 1.07; 58 women). More women receiving Danxioling experienced marked improvement in pruritus in comparison to the Yiganling group (MD 1.67, 95% CI 1.14 to 2.44; 58 women). <i>See</i><a href="./references#CD000493-fig-0104" title="">Analysis 14.1</a>. </p> </section> </section> <section id="CD000493-sec-0276"> <h5 class="title">Primary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0277"> <h6 class="title">Stillbirth/neonatal death</h6> <p>There were no stillbirths or neonatal deaths in either group (<a href="./references#CD000493-fig-0105" title="">Analysis 14.2</a>). </p> </section> <section id="CD000493-sec-0278"> <h6 class="title">Fetal distress/asphyxial events</h6> <p><a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a> did not report this outcome. </p> </section> </section> <section id="CD000493-sec-0279"> <h5 class="title">Secondary outcomes (maternal)</h5> <section id="CD000493-sec-0280"> <h6 class="title">Biochemical assessments</h6> <p><a href="./references#CD000493-bbs2-0022" title="ShiDY , ChenH , XiaoM . Observation on the effect of danxiaoling in supplementary treatment of intrahepatic cholestasis in pregnancy. Zhongguo Zhong Xi Yi Jie He Za Zhi2002;22(2):116-8. ">Shi 2002</a> found little to no difference in the concentrations of serum bile acids (MD −3.83, 95% CI −22.59 to 14.93; 58 women; <a href="./references#CD000493-fig-0106" title="">Analysis 14.3</a>), or of serum ALT (MD 5.20, 95% CI −36.90 to 47.30; 54 women; <a href="./references#CD000493-fig-0107" title="">Analysis 14.4</a>). </p> </section> <section id="CD000493-sec-0281"> <h6 class="title">Caesarean section</h6> <p>Few to no differences were seen between the Danxioling and Yiganling groups for the incidence of caesarean section (RR 0.60, 95% CI 0.16 to 2.28; 58 women; <a href="./references#CD000493-fig-0108" title="">Analysis 14.5</a>). </p> </section> </section> <section id="CD000493-sec-0282"> <h5 class="title">Secondary outcomes (fetal/neonatal)</h5> <section id="CD000493-sec-0283"> <h6 class="title">Meconium‐stained liquor</h6> <p>A lower incidence of meconium‐stained liquor was observed in the group receiving Danxioling in comparison with the group receiving Yiganling (RR 0.40, 95% CI 0.18 to 0.89; 58 women; <a href="./references#CD000493-fig-0109" title="">Analysis 14.6</a>). </p> </section> <section id="CD000493-sec-0284"> <h6 class="title">Spontaneous birth at less than 37 weeks</h6> <p>There was little to no difference in the rates of spontaneous preterm births between the two groups (RR 0.33, 95% CI 0.04 to 3.02; 58 women; <a href="./references#CD000493-fig-0110" title="">Analysis 14.7</a>). </p> <p>The following secondary outcomes were not reported: postpartum haemorrhage, adverse effects of medication, mean gestational age at birth, total preterm birth or admission to neonatal unit. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000493-sec-0285" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000493-sec-0285"></div> <section id="CD000493-sec-0286"> <h3 class="title" id="CD000493-sec-0286">Summary of main results</h3> <p>With the addition of <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>, there is moderate‐certainty evidence for the effect of ursodeoxycholic acid (UDCA) in women with intrahepatic cholestasis of pregnancy on pruritus. The certainty of the evidence is very low for stillbirth because of serious concerns about limitations in study design and imprecision of results from very small unregistered trials. The certainty of the evidence is also very low for fetal distress/asphyxial events, again because of limitations in study design and the imprecision of results for this outcome. For all other treatments the certainty of the evidence for outcomes remains low. </p> <p>Two placebo‐controlled trials of UDCA have now reported a small reduction in itching as a prespecified outcome across all women with intrahepatic cholestasis of pregnancy (moderate‐certainty evidence). However, both show a small effect well below the size which most women and healthcare professionals might regard as worthwhile. </p> <p>UDCA may also be more effective in improving pruritus than either S‐adenosylmethionine (SAMe) or cholestyramine, and a combination of UDCA and SAMe may be more effective than SAMe and placebo, but the certainty of the evidence is low. Pruritus was reduced with Danxioling when compared with Yiganling, but the use of these medicines is currently limited to East Asia. Information on safety and efficacy, and further evidence from well‐designed randomised controlled trials, are needed before the use of these drugs can be adopted globally. The results for pruritus improvement from trials comparing other interventions were either inconsistent or showed no evidence of an effect. </p> <p>Six trials comparing UDCA with placebo reported fetal or neonatal deaths, with seven deaths reported overall (six in the placebo, one in the intervention groups). This difference may have occurred by chance. Four of the six stillbirths in the placebo groups occurred in small unregistered trials (<a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0018" title="MengLJ , ReyesH , AxelsonM , PalmaJ , HernandezI , RibaltaJ , et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology1997;26(6):1573-9. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , AlumnaR , et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. Journal of Hepatology1997;27(6):1022-8. PalmaJ , ReyesH , RibaltaJ , HernandezI , SandovalL , SilvaO , et al. Ursodeoxycholic acid in cholestasis of pregnancy: final report of a randomized, double-blind, placebo controlled study. Hepatology1996;24(4 Pt 2):373A. ">Palma 1997</a>; <a href="./references#CD000493-bbs2-0024" title="WangDZ , ChenJ . Study of ursodeoxycholic acid in 64 patients with intrahepatic cholestasis of pregnancy. Journal of Practical Medical Techniques2003;10(9):991-2. ">Wang 2003</a>), and it is unclear whether one of the stillbirths was attributable to intrahepatic cholestasis of pregnancy. In the largest placebo‐controlled trial (<a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>), two deaths occurred in placebo groups versus one in the UDCA groups. </p> <p>There were fewer instances of fetal distress in the UDCA groups compared with placebo, but the certainty of the evidence is very low and the definition of 'fetal distress' varied across trials. When the analysis was restricted to the two studies at low risk of bias, the intervention effect disappeared and no difference was seen in instances of fetal distress between the groups. In the UDCA groups, the rates of passage of meconium‐stained liquor were lower and the mean gestational age at birth was higher, but neither clearly different. </p> <p>The rates of fetal distress within other comparisons were all based on low‐certainty evidence. With this proviso, they were similar when UDCA was compared with SAMe, with cholestyramine and with UDCA + salvia. The group receiving combined UDCA + SAMe had fewer instances of fetal distress/asphyxial events when compared with the group randomised to UDCA or SAMe monotherapy. The rates of fetal distress were higher in the group receiving dexamethasone when compared with both UDCA and placebo. </p> </section> <section id="CD000493-sec-0287"> <h3 class="title" id="CD000493-sec-0287">Overall completeness and applicability of evidence</h3> <p>The 26 studies included in this review are spread over 14 comparisons. In only two comparisons was it possible to include more than two trials, with seven studies comparing UDCA versus placebo, and four trials comparing UDCA versus SAMe. Unfortunately in the four trials comparing SAMe versus placebo only single study analyses were possible. In the remaining trials, it was not possible to answer reliably how beneficial the relative merits of the interventions are, because of the paucity of data.  </p> </section> <section id="CD000493-sec-0288"> <h3 class="title" id="CD000493-sec-0288">Quality of the evidence</h3> <p>The risks of bias of the studies included in this review ranged from low to high. Two large studies comparing UDCA with placebo had a low risk of bias (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>). The remainder had a high or uncertain risk of bias. </p> <p>Due to the varying methods of measuring and reporting pruritus, pooling of data for this outcome was only possible for the <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> and <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a> trials (moderate‐certainty evidence). Eight trials (40%) used a 0 ‐ 4 scale for pruritus assessment and analysed it as a continuous outcome, which may not be an appropriate method for such a short scale. Dichotomisation of these data and re‐analysis was possible in only one trial. One trial did not specify the methods used for assessing pruritus. Pruritus score was assessed as being of moderate certainty, with downgrading of the evidence due to imprecision. For stillbirth and fetal distress/asphyxial events the evidence was assessed as being of very low certainty with very serious concerns due to limitations in study design and serious imprecision. </p> </section> <section id="CD000493-sec-0289"> <h3 class="title" id="CD000493-sec-0289">Potential biases in the review process</h3> <p>The evidence for this review is derived from studies identified in a detailed search process. We are confident that the search has identified all relevant trials. Two of the review authors are co‐authors of included trials (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>) and four of the review authors are investigators on ongoing trials (TURRIFIC study). These trials were and will be assessed independently by review authors not involved in them. </p> </section> <section id="CD000493-sec-0290"> <h3 class="title" id="CD000493-sec-0290">Agreements and disagreements with other studies or reviews</h3> <p>The first version of this review (<a href="./references#CD000493-bbs2-0128" title="BurrowsRF , ClavisiO , BurrowsE . Interventions for treating cholestasis in pregnancy. Cochrane Database of Systematic Reviews2001, Issue 4. Art. No: CD000493. [DOI: 10.1002/14651858.CD000493]">Burrows 2001</a>) included just nine randomised controlled trials with data from 227 women. In summary, the authors found insufficient evidence for any of the interventions, alone or in combination in treating women with intrahepatic cholestasis of pregnancy. The previous update (<a href="./references#CD000493-bbs2-0129" title="GurungV , StokesM , MiddletonP , MilanSJ , HagueW , ThorntonJG . Interventions for treating cholestasis in pregnancy. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD000493. [DOI: 10.1002/14651858.CD000493.pub2]">Gurung 2013</a>) included three new comparisons between UDCA and placebo (<a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>; <a href="./references#CD000493-bbs2-0009" title="GlantzA , MarschallHU , LammertF , MattssonLA . Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology2005;42(6):1399-405. GlantzA , ReillySJ , BenthinL , LammertF , MattssonLA , MarschallHU . Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. Hepatology2008;47(2):376-9. ">Glantz 2005</a>; <a href="./references#CD000493-bbs2-0015" title="LiuY , QiaoF , LiuH , LiuD . Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Journal of Huazhong University of Science and Technology. Medical Sciences2006;26(3):350-2. ">Liu 2006</a>), but concluded only that the small reduction in pruritus scores was real. A meta‐analysis comparing UDCA with SAMe (<a href="./references#CD000493-bbs2-0127" title="ZhangY , LuL , VictorDW , XinY , XuanS . Ursodeoxycholic acid and S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy: a meta-analysis. Hepatitis Monthly2016;16(8):e38558.">Zhang 2016</a>), which did not include <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a> and which was published before <a href="./references#CD000493-bbs2-0003" title="ChappellL , EUCTR2014-004478-41-GB. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes - PITCHES: Phase III trial of UDCA in ICP: V1. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004478-412015. ChappellLC , BellJL , SmithA , LinsellL , JuszczakE , DixonPH , et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet2019;394(10201):849-60. ChappellLC , ChambersJ , DixonPH , DorlingJ , HunterR , BellJL , et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (icp) to improve perinatal outcomes: protocol for a randomised controlled trial (pitches). Trials2018;19(1):657. SmithA , ISRCTN91918806. Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes. www.isrctn.com/ISRCTN91918806 (first received 26 August 2015). ">Chappell 2019</a>, suggested that UDCA was more effective than SAMe in reducing pruritus and preterm birth. Another meta‐analysis (<a href="./references#CD000493-bbs2-0078" title="KongX , KongY , ZhangF , WangT , YanJ . Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy. A meta-analysis (a prisma-compliant study). Medicine (Baltimore)2016;95(40):e4949.">Kong 2016</a>) concluded that UDCA improved pruritus and liver function and reduced adverse maternal and fetal outcomes in pregnant women with ICP. However, the authors of that review graded the risks of bias for many of the included studies as being much higher than we did. A meta‐analysis of UDCA versus other drugs (<a href="./references#CD000493-bbs2-0043" title="BacqY , SentilhesL , ReyesHB , GlantzA , KondrackieneJ , BinderT , et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology2012;143(6):1492-501. [DOI: doi.org/10.1053/j.gastro.2012.08.004] [PMID: 22892336]">Bacq 2012</a>) concluded that UDCA is effective in improving pruritus, and liver function may improve fetal outcomes; it did not include <a href="./references#CD000493-bbs2-0002" title="ChappellLC , GurungV , ChambersJ , SeedPT , WilliamsonC , ThorntonJG . PITCH: Two randomised controlled trials in obstetric cholestasis: Ursodeoxycholic acid versus placebo and early delivery versus expectant management. Archives of Disease in Childhood: Fetal and Neonatal Edition2011;96:Fa110-Fa111. ChappellLC , GurungV , SeedPT , ChambersJ , WilliamsonC , ThorntonJG . Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ2012;344:e3799. GurungV , ChappellL , SeedP , ChambersJ , WilliamsonC , ThorntonJ . Pitch: Ursodeoxycholic acid versus placebo, and early delivery versus expectant management in the management of intrahepatic cholestasis of pregnancy: two randomised controlled trials. International Journal of Gynecology and Obstetrics2012;119(Suppl 3):S363-4. GurungV , WilliamsonC , ChappellL , ChambersJ , BrileyA , Broughton PipkinF , et al. Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis. BMC Pregnancy and Childbirth2009;9:19. Nelson-PiercyC . Obstetric cholestasis. BJOG: an international journal of obstetrics and gynaecology2008;115(s1):20. ThorntonG , GurungV , ChappellC , WilliamsonC , ChambersJ . Ursodeoxycholic acid versus placebo, and early delivery versus expectant management, in women with obstetric cholestasis: two semi-factorial randomised clinical trials. Journal of Maternal-Fetal and Neonatal Medicine2012;25(S2):100-1. WilliamsonC , ChappellLC , GurungV , ChambersJ , SeedPT , ThorntonJG . Pitch: Two randomised controlled trials in intrahepatic cholestasis of pregnancy: ursodeoxycholic acid vs. placebo and early delivery vs. expectant management. Hepatology2011;54(4 Suppl):925A. ">Chappell 2012</a>. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000493-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD000493-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD000493-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000493-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 1: Mean of worst itching scores over preceding 24 hours between randomisation and delivery" data-id="CD000493-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 1: Mean of worst itching scores over preceding 24 hours between randomisation and delivery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 2: Pruritus improvement" data-id="CD000493-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 2: Pruritus improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 3: Mean of average itching scores over preceding 24 hours between randomisation and delivery" data-id="CD000493-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 3: Mean of average itching scores over preceding 24 hours between randomisation and delivery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 4: Stillbirth" data-id="CD000493-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 4: Stillbirth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 5: Fetal distress/asphyxial event" data-id="CD000493-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 5: Fetal distress/asphyxial event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 6: Subgroup analysis ‐ fetal distress/asphyxial events" data-id="CD000493-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 6: Subgroup analysis ‐ fetal distress/asphyxial events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 7: Change in bile acid concentration, µmol/L" data-id="CD000493-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 7: Change in bile acid concentration, µmol/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 8: ALT, IU/L" data-id="CD000493-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 8: ALT, IU/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 9: ALT reduction, IU/L" data-id="CD000493-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 9: ALT reduction, IU/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 10: Caesarean section" data-id="CD000493-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 10: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 11: Postpartum haemorrhage" data-id="CD000493-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 11: Postpartum haemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 12: Adverse effects of medication" data-id="CD000493-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 12: Adverse effects of medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 13: Meconium‐stained liquor" data-id="CD000493-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 13: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 14: Mean gestational age at birth (weeks)" data-id="CD000493-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 14: Mean gestational age at birth (weeks)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 15: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 15: Spontaneous birth at less than 37 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 16: Total preterm birth at less than 37 weeks" data-id="CD000493-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 16: Total preterm birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: UDCA versus placebo, Outcome 17: Admission to neonatal intensive care unit" data-id="CD000493-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: UDCA versus placebo, Outcome 17: Admission to neonatal intensive care unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SAMe versus placebo, Outcome 1: Stillbirth/neonatal death" data-id="CD000493-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: SAMe versus placebo, Outcome 1: Stillbirth/neonatal death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SAMe versus placebo, Outcome 2: Bile acid reduction, µmol/L" data-id="CD000493-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: SAMe versus placebo, Outcome 2: Bile acid reduction, µmol/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SAMe versus placebo, Outcome 3: ALT reduction, IU/L" data-id="CD000493-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: SAMe versus placebo, Outcome 3: ALT reduction, IU/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SAMe versus placebo, Outcome 4: Caesarean section" data-id="CD000493-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: SAMe versus placebo, Outcome 4: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SAMe versus placebo, Outcome 5: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: SAMe versus placebo, Outcome 5: Spontaneous birth at less than 37 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: SAMe versus placebo, Outcome 6: Total preterm birth at less than 37 weeks" data-id="CD000493-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: SAMe versus placebo, Outcome 6: Total preterm birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Guar gum versus placebo, Outcome 1: Pruritus improvement" data-id="CD000493-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Guar gum versus placebo, Outcome 1: Pruritus improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Guar gum versus placebo, Outcome 2: Total bile acids (µmol/L)" data-id="CD000493-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Guar gum versus placebo, Outcome 2: Total bile acids (µmol/L)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Guar gum versus placebo, Outcome 3: ALT, U/L" data-id="CD000493-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Guar gum versus placebo, Outcome 3: ALT, U/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Guar gum versus placebo, Outcome 4: Adverse effects of medication" data-id="CD000493-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Guar gum versus placebo, Outcome 4: Adverse effects of medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Guar gum versus placebo, Outcome 5: Mean gestational age at birth" data-id="CD000493-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Guar gum versus placebo, Outcome 5: Mean gestational age at birth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Activated charcoal versus no treatment, Outcome 1: Pruritus improvement" data-id="CD000493-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Activated charcoal versus no treatment, Outcome 1: Pruritus improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Activated charcoal versus no treatment, Outcome 2: Bile acids after 8 days treatment, µmol/L" data-id="CD000493-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Activated charcoal versus no treatment, Outcome 2: Bile acids after 8 days treatment, µmol/L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Activated charcoal versus no treatment, Outcome 3: ALT after 8 days treatment, U/L" data-id="CD000493-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Activated charcoal versus no treatment, Outcome 3: ALT after 8 days treatment, U/L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Activated charcoal versus no treatment, Outcome 4: Mean gestational age at birth" data-id="CD000493-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Activated charcoal versus no treatment, Outcome 4: Mean gestational age at birth </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dexamethasone versus placebo, Outcome 1: Stillbirths" data-id="CD000493-fig-0036" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Dexamethasone versus placebo, Outcome 1: Stillbirths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dexamethasone versus placebo, Outcome 2: Fetal distress/asphyxial event" data-id="CD000493-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Dexamethasone versus placebo, Outcome 2: Fetal distress/asphyxial event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dexamethasone versus placebo, Outcome 3: Subgroup analysis ‐ fetal distress/asphyxial event" data-id="CD000493-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Dexamethasone versus placebo, Outcome 3: Subgroup analysis ‐ fetal distress/asphyxial event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dexamethasone versus placebo, Outcome 4: Meconium‐stained liquor" data-id="CD000493-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Dexamethasone versus placebo, Outcome 4: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dexamethasone versus placebo, Outcome 5: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Dexamethasone versus placebo, Outcome 5: Spontaneous birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dexamethasone versus placebo, Outcome 6: Total preterm births at less than 37 weeks" data-id="CD000493-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Dexamethasone versus placebo, Outcome 6: Total preterm births at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 1: Pruritus improvement" data-id="CD000493-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 1: Pruritus improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 2: Mean pruritus score one week post treatment" data-id="CD000493-fig-0043" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 2: Mean pruritus score one week post treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 3: Mean pruritus score two weeks post treatment" data-id="CD000493-fig-0044" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 3: Mean pruritus score two weeks post treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 4: Fetal distress/asphyxial events" data-id="CD000493-fig-0045" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 4: Fetal distress/asphyxial events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 5: Bile acids, µmol/L" data-id="CD000493-fig-0046" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 5: Bile acids, µmol/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 6: ALT, µkatl/L" data-id="CD000493-fig-0047" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 6: ALT, µkatl/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 7: Caesarean section" data-id="CD000493-fig-0048" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 7: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 8: Meconium‐stained liquor" data-id="CD000493-fig-0049" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 8: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 9: Mean gestational age at birth" data-id="CD000493-fig-0050" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 9: Mean gestational age at birth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 10: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0051" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 10: Spontaneous birth at less than 37 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 11: Total preterm birth at less than 37 weeks" data-id="CD000493-fig-0052" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 11: Total preterm birth at less than 37 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-006.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: UDCA versus SAMe, Outcome 12: Admission to neonatal intensive care unit" data-id="CD000493-fig-0053" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-006.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6: UDCA versus SAMe, Outcome 12: Admission to neonatal intensive care unit</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-006.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: UDCA versus dexamethasone, Outcome 1: Fetal distress/asphyxial events" data-id="CD000493-fig-0054" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: UDCA versus dexamethasone, Outcome 1: Fetal distress/asphyxial events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: UDCA versus dexamethasone, Outcome 2: Adverse effects of medication" data-id="CD000493-fig-0055" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: UDCA versus dexamethasone, Outcome 2: Adverse effects of medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: UDCA versus dexamethasone, Outcome 3: Meconium‐stained liquor" data-id="CD000493-fig-0056" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: UDCA versus dexamethasone, Outcome 3: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: UDCA versus dexamethasone, Outcome 4: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0057" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: UDCA versus dexamethasone, Outcome 4: Spontaneous birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: UDCA versus dexamethasone, Outcome 5: Total preterm birth at less than 37 weeks" data-id="CD000493-fig-0058" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: UDCA versus dexamethasone, Outcome 5: Total preterm birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 1: Pruritus score (&gt; 50% reduction after 14 days treatment)" data-id="CD000493-fig-0059" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 1: Pruritus score (&gt; 50% reduction after 14 days treatment) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 2: Fetal distress/asphyxial event" data-id="CD000493-fig-0060" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 2: Fetal distress/asphyxial event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 3: Bile acids, µmol/L" data-id="CD000493-fig-0061" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 3: Bile acids, µmol/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 4: ALT, U/L" data-id="CD000493-fig-0062" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 4: ALT, U/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 5: Caesarean section" data-id="CD000493-fig-0063" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 5: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 6: Adverse effects of medication" data-id="CD000493-fig-0064" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 6: Adverse effects of medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 7: Mean gestational age at birth" data-id="CD000493-fig-0065" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 7: Mean gestational age at birth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-008.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: UDCA versus cholestyramine, Outcome 8: Total preterm birth at less than 37 weeks" data-id="CD000493-fig-0066" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-008.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8: UDCA versus cholestyramine, Outcome 8: Total preterm birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-008.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: UDCA + SAMe versus placebo, Outcome 1: Bile acid reduction at 20 days, µmol/L" data-id="CD000493-fig-0067" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: UDCA + SAMe versus placebo, Outcome 1: Bile acid reduction at 20 days, µmol/L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 1: Pruritus improvement" data-id="CD000493-fig-0068" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 1: Pruritus improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 2: Stillbirths/neonatal deaths" data-id="CD000493-fig-0069" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 2: Stillbirths/neonatal deaths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 3: Fetal distress/asphyxial event" data-id="CD000493-fig-0070" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 3: Fetal distress/asphyxial event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 4: Bile acids, µmol/L" data-id="CD000493-fig-0071" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 4: Bile acids, µmol/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 5: ALT, µkatl/L" data-id="CD000493-fig-0072" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 5: ALT, µkatl/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 6: Caesarean section" data-id="CD000493-fig-0073" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 6: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 7: Postpartum haemorrhage" data-id="CD000493-fig-0074" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 7: Postpartum haemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 8: Meconium‐stained liquor" data-id="CD000493-fig-0075" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 8: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 9: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0076" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.9</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 9: Spontaneous birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 10: Total preterm birth at less than 37 weeks" data-id="CD000493-fig-0077" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.10</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 10: Total preterm birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-010.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: UDCA + SAMe versus SAMe, Outcome 11: Admission to neonatal intensive care unit" data-id="CD000493-fig-0078" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-010.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.11</div> <div class="figure-caption"> <p>Comparison 10: UDCA + SAMe versus SAMe, Outcome 11: Admission to neonatal intensive care unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-010.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 1: Pruritus improvement" data-id="CD000493-fig-0079" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 1: Pruritus improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 2: Mean pruritus score post treatment" data-id="CD000493-fig-0080" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 2: Mean pruritus score post treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 3: Stillbirths/neonatal deaths" data-id="CD000493-fig-0081" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 3: Stillbirths/neonatal deaths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 4: Fetal distress/asphyxial event" data-id="CD000493-fig-0082" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 4: Fetal distress/asphyxial event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 5: Bile acids, µmol/L" data-id="CD000493-fig-0083" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 5: Bile acids, µmol/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 6: ALT, µkatl/L" data-id="CD000493-fig-0084" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 6: ALT, µkatl/L</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 7: Reduction in ALT (IU/L) after treatment" data-id="CD000493-fig-0085" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 7: Reduction in ALT (IU/L) after treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 8: Caesarean section" data-id="CD000493-fig-0086" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 8: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 9: Postpartum haemorrhage" data-id="CD000493-fig-0087" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.9</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 9: Postpartum haemorrhage</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 10: Meconium‐stained liquor" data-id="CD000493-fig-0088" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.10</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 10: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 11: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0089" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.11</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 11: Spontaneous birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 12: Total preterm births at less than 37 weeks" data-id="CD000493-fig-0090" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.12</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 12: Total preterm births at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-011.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: UDCA + SAMe versus UDCA, Outcome 13: Admission to neonatal intensive care unit" data-id="CD000493-fig-0091" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-011.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.13</div> <div class="figure-caption"> <p>Comparison 11: UDCA + SAMe versus UDCA, Outcome 13: Admission to neonatal intensive care unit </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-011.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: UDCA + Salvia versus UDCA, Outcome 1: Reduction in pruritus from moderate/severe to mild (0‐4 scale)" data-id="CD000493-fig-0092" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: UDCA + Salvia versus UDCA, Outcome 1: Reduction in pruritus from moderate/severe to mild (0‐4 scale) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: UDCA + Salvia versus UDCA, Outcome 2: Reduction in ALT (IU/L) after treatment" data-id="CD000493-fig-0093" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: UDCA + Salvia versus UDCA, Outcome 2: Reduction in ALT (IU/L) after treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: UDCA + Salvia versus UDCA, Outcome 3: Meconium‐stained liquor" data-id="CD000493-fig-0094" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: UDCA + Salvia versus UDCA, Outcome 3: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: UDCA + Salvia versus UDCA, Outcome 4: Fetal distress" data-id="CD000493-fig-0095" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: UDCA + Salvia versus UDCA, Outcome 4: Fetal distress</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 1: Degree of pruritus after treatment" data-id="CD000493-fig-0096" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 1: Degree of pruritus after treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 2: Stillbirths/neonatal deaths" data-id="CD000493-fig-0097" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 2: Stillbirths/neonatal deaths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 3: Fetal distress/asphyxial event" data-id="CD000493-fig-0098" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 3: Fetal distress/asphyxial event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 4: Bile salt (CGA) concentration" data-id="CD000493-fig-0099" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 4: Bile salt (CGA) concentration</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 5: ALT" data-id="CD000493-fig-0100" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 5: ALT</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 6: Caesarean section" data-id="CD000493-fig-0101" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 6: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 7: Meconium‐stained liquor" data-id="CD000493-fig-0102" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 7: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-013.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: YCHD versus SAMe, Outcome 8: Mean gestational age at birth" data-id="CD000493-fig-0103" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-013.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13: YCHD versus SAMe, Outcome 8: Mean gestational age at birth</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-013.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Danxioling versus Yiganling, Outcome 1: Pruritus" data-id="CD000493-fig-0104" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Danxioling versus Yiganling, Outcome 1: Pruritus</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Danxioling versus Yiganling, Outcome 2: Stillbirths/neonatal deaths" data-id="CD000493-fig-0105" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Danxioling versus Yiganling, Outcome 2: Stillbirths/neonatal deaths</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Danxioling versus Yiganling, Outcome 3: Bile acid concentration (CGA)" data-id="CD000493-fig-0106" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Danxioling versus Yiganling, Outcome 3: Bile acid concentration (CGA)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Danxioling versus Yiganling, Outcome 4: ALT" data-id="CD000493-fig-0107" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: Danxioling versus Yiganling, Outcome 4: ALT</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Danxioling versus Yiganling, Outcome 5: Caesarean section" data-id="CD000493-fig-0108" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: Danxioling versus Yiganling, Outcome 5: Caesarean section</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-014.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Danxioling versus Yiganling, Outcome 6: Meconium‐stained liquor" data-id="CD000493-fig-0109" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-014.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14: Danxioling versus Yiganling, Outcome 6: Meconium‐stained liquor</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000493-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/urn:x-wiley:14651858:media:CD000493:CD000493-CMP-014.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Danxioling versus Yiganling, Outcome 7: Spontaneous birth at less than 37 weeks" data-id="CD000493-fig-0110" src="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_t/tCD000493-CMP-014.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.7</div> <div class="figure-caption"> <p>Comparison 14: Danxioling versus Yiganling, Outcome 7: Spontaneous birth at less than 37 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/media/CDSR/CD000493/image_n/nCD000493-CMP-014.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000493-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ursodeoxycholic acid (UDCA) versus placebo</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Ursodeoxycholic acid (UDCA)</b> <b>compared with placebo</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> pregnant women with intrahepatic cholestasis </p> <p><b>Settings:</b> UK (2 RCTs), Chile, China, Finland, Italy, Sweden (one RCT each) </p> <p><b>Intervention:</b> UDCA </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>UDCA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pruritus score*</p> <p>(points out of 100 mm visual analogue scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean of the worst pruritus score in the placebo group ranged from 56.9 to 61.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean of the worst pruritus score in the intervention groups was 7.64 lower (9.69 lower to 5.60 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>715 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>*worst score in previous 24 hours</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stillbirth</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9/1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.51/1000 (0.72 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33 (0.08 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>955 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a small number of events and a wide CI</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fetal distress/asphyxial events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117/1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82/1000 (41 to 164)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70 (0.35 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>944 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>very low<sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>MD:</b> Mean difference; <b>RR:</b> Risk ratio; <b>UDCA:</b> ursodeoxycholic acid. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded one level for serious imprecision, due to there being only two trials, one relatively small.<br/><sup>b</sup> We downgraded two levels for very serious limitations in study design, due to two RCTs not having adequate randomisation and a third RCT with high losses to follow‐up.<br/><sup>c</sup>We downgraded one level for serious imprecision, due to a small number of events and wide confidence intervals.<br/><sup>d</sup>We downgraded one level for serious imprecision, due to wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ursodeoxycholic acid (UDCA) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/full#CD000493-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">UDCA versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mean of worst itching scores over preceding 24 hours between randomisation and delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.64 [‐9.69, ‐5.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Pruritus improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mean of average itching scores over preceding 24 hours between randomisation and delivery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Stillbirth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Fetal distress/asphyxial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.35, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Subgroup analysis ‐ fetal distress/asphyxial events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Bile acid levels &lt; 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Bile acid levels ≥ 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Change in bile acid concentration, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.45 [‐26.07, ‐14.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 ALT, IU/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐68.73 [‐104.09, ‐33.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 At two weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐90.21 [‐101.96, ‐78.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 At three weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐98.65 [‐217.02, 19.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 ALT post randomisation, exact time not defined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐37.90 [‐60.85, ‐14.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 ALT reduction, IU/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>84.83 [70.61, 99.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 At 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>84.83 [70.61, 99.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.76, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Adverse effects of medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.56, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Mean gestational age at birth (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.20, 2.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Total preterm birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.37, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.55, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">UDCA versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">SAMe versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Stillbirth/neonatal death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Bile acid reduction, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 At 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 ALT reduction, IU/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 At 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Total preterm birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">SAMe versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Guar gum versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pruritus improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Participant assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Clinician assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Total bile acids (µmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 ALT, U/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Adverse effects of medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Mean gestational age at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Guar gum versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Activated charcoal versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Pruritus improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Bile acids after 8 days treatment, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 ALT after 8 days treatment, U/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Mean gestational age at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Activated charcoal versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dexamethasone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Stillbirths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Fetal distress/asphyxial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Subgroup analysis ‐ fetal distress/asphyxial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Bile acid levels &lt; 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Bile acid levels ≥ 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Any degree of ICP (all women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Severe subgroup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Bile acid levels &lt; 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Bile acid levels ≥ 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Total preterm births at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Bile acid levels &lt; 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Bile acid levels ≥ 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dexamethasone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">UDCA versus SAMe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Pruritus improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Any improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.83, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Marked improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.00, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 Complete resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.00 [1.40, 315.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.4 Complete resolution or marked improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.68 [0.26, 83.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Mean pruritus score one week post treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.61, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Mean pruritus score two weeks post treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.82, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Fetal distress/asphyxial events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.25, 3.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Bile acids, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 After 3‐4 weeks treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.00 [‐43.67, ‐10.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 Reduction after 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [‐3.96, 7.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.3 After 1 week treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.40 [‐14.86, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.4 After 2 weeks treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.14 [‐14.74, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 ALT, µkatl/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐3.58, ‐0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 After 3‐4 weeks treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐3.55, ‐0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 After 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐52.58 [‐116.40, 11.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.65, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.20, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Mean gestational age at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.84, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.22, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 Total preterm birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.35, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.12 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.26, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">UDCA versus SAMe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">UDCA versus dexamethasone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Fetal distress/asphyxial events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Bile acid levels &lt; 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Bile acid levels ≥ 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Adverse effects of medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.60, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.29, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Total preterm birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.44, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.1 Bile acid levels &lt; 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.23, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5.2 Bile acid levels ≥ 40 µmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.52, 3.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">UDCA versus dexamethasone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">UDCA versus cholestyramine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Pruritus score (&gt; 50% reduction after 14 days treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Fetal distress/asphyxial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Bile acids, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 ALT, U/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Adverse effects of medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Mean gestational age at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.8 Total preterm birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">UDCA versus cholestyramine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">UDCA + SAMe versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Bile acid reduction at 20 days, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">UDCA + SAMe versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">UDCA + SAMe versus SAMe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Pruritus improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Any improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.2 Marked improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Stillbirths/neonatal deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Fetal distress/asphyxial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Bile acids, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 After 3‐4 weeks treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.00 [‐40.16, ‐9.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.2 Reduction at 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.20 [16.43, 31.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 ALT, µkatl/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 After 3‐4 weeks treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.6 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.7 Postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.8 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.9 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.10 Total preterm birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.11 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">UDCA + SAMe versus SAMe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">UDCA + SAMe versus UDCA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Pruritus improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 Any improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 Marked improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Mean pruritus score post treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Stillbirths/neonatal deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Fetal distress/asphyxial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.03, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Bile acids, µmol/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 After 3‐4 weeks treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐33.00 [‐34.46, ‐31.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.2 Reduction at 20 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.30 [2.16, 20.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.6 ALT, µkatl/L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6.1 After 3‐4 weeks treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.7 Reduction in ALT (IU/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.15, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.8 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.35, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.9 Postpartum haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.10 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.34, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.11 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.12 Total preterm births at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.13 Admission to neonatal intensive care unit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">UDCA + SAMe versus UDCA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">UDCA + Salvia versus UDCA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Reduction in pruritus from moderate/severe to mild (0‐4 scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Reduction in ALT (IU/L) after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Fetal distress <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">UDCA + Salvia versus UDCA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">YCHD versus SAMe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Degree of pruritus after treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 Marked improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Stillbirths/neonatal deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Fetal distress/asphyxial event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Bile salt (CGA) concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.5 ALT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.6 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.7 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.8 Mean gestational age at birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">YCHD versus SAMe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000493-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Danxioling versus Yiganling</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Pruritus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Any improvement after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 Marked improvement after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Stillbirths/neonatal deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Bile acid concentration (CGA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 ALT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 Caesarean section <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.6 Meconium‐stained liquor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.7 Spontaneous birth at less than 37 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Danxioling versus Yiganling</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000493.pub3/references#CD000493-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000493.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000493-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000493-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000493-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000493-note-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD000493-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD000493-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000493-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000493\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000493\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000493\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000493\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000493\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000493.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000493.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000493.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000493.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000493.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714802481"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000493.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714802485"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000493.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d77928e6c937d',t:'MTc0MDcxNDgwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 